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Abstract
Polymorphonuclear leukocytes (PMN) express a receptor of the integrin
family termed complement receptor type 3 (CR3, also known as ocMp2, Mac-1,
Mol or CDllb/CD18) that functions in several cell-cell and cell-substratum
adhesion events. The capacity of CR3 to mediate adhesion may be rapidly and
reversibly enhanced without changes in the number of receptors expressed on
the cell surface. This thesis describes an acidic, amphiphilic lipid, termed
integrin modulating factor (IMF-1), that may serve to control CR3 avidity.
Addition of IMF-1 to cells or to purified CR3 causes enhanced binding of
ligand. IMF-1 cannot be extracted from resting PMN but can be extracted
from cells within one minute of stimulation with a variety of agonists (PMA,
TNF, formylated peptides, platelet activating factor). The amount of IMF-1
extracted declines to low levels within an hour of continued stimulation. The
time course of IMF-1 extraction corresponds precisely with the transient
increase in the adhesive activity of CR3 observed in PMN stimulated with
these agonists. IMF-1 can also increase the binding activity of another
leukocyte integrin, LFA-1 (aLp2, CD1WCD18). However, IMF-1 does not
affect the function of representative P1 and p3 integrins. IMF-1 has a
molecular weight of 340 + 16 daltons by size exclusion chromatography and
appears to be distinct from the known lipid products of PMN. The data
suggest that PMN control their adhesivity through a novel lipid that may act
as an allosteric activator of leukocyte integrins.
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Chapter 1 - Introduction
Inflammation
Inflammation occurs in tissues in response to infection or chemical or
physical trauma. Massive influx of inflammatory cells, including the
polymorphonuclear leukocyte (PMN) is a hallmark of the inflammatory
response. In the 1st century, A.D., Cornelius Celsus noted the four cardinal
signs of inflammation that result from this leukocytic infiltration as well as
changes in vascular flow and permeability: rubor (redness), tumor (edema),
color (heat) and dolor (pain). A fifth clinical sign, function laeso (loss of
function) was later added by Virchow (Cotran et al.,1989). The cells of the
inflammatory response clear infectious agents or other foreign substances,
eliminate or repair dead or damaged tissues and, due to their potent
destructive ability, may sometimes damage nearby normal tissues, resulting
in disease.
The role of the neutrophil in inflammation
PMN play a central role in the inflammatory response (figure 1) (Malech
and Gallin, 1987). At the inflammatory site, PMN release products of the
oxidative burst such as hydrogen peroxide and free radicals, which attack and
digest the triggering agent. PMN also release lytic and bactericidal enzymes
from intracellular granules as well as mediators that recruit more PMN to the
site as well as other inflammatory cells involved in later phases of the
response. Finally, PMN can phagocytose bacteria and cells, killing them by
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Figure 1. Neutrophil responses to infection or other causes of inflammation.
(from Malech and Gallin, 1987)
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release of intracellular mediators into the phagosome. All of these vital
functions of PMN require the cell to leave the vasculature to reach the site of
inflammation.
Interactions of the neutrophil with the endothelium
The migration of leukocytes into tissues, also referred to as diapedesis,
is a key event in the inflammatory response. Normally, PMN circulate freely
in the blood and do not interact with the endothelial cells (EC) lining the
vessel. In response to a wide range of activators and chemotactic factors,
PMN become adherent to EC and migrate within seconds (average 56 seconds,
range of 15 to 150 seconds) out of the bloodstream and into the tissue (Huang
et al.,1988).
The process of diapedesis begins with margination of the neutrophil: the
cells leave the central stream of flowing blood in a postcapillary venule and
begin rolling along on the endothelium. Margination occurs within minutes
of injury to adjacent tissue, as determined using intravital microscopy
(Cohnheim, 1889). The postcapillary venule is the predominant site of
diapedesis in inflammation; in a healthy individual it is devoid of marginating
cells (Fiebig et al.,1991). Margination in the postcapillary venule is different
from the "marginated pool" of approximately 50% of PMN that remain in
capillary beds in the lungs and tissues, entering the circulation in response to
exercise or adrenaline.
As the inflammatory reaction progresses, the round rolling PMN
accumulate on the endothelium and come to a halt, at which point they
4

undergo a marked change in shape, flattening against the vessel wall and
extending pseudopods into the intercellular junctions of EC (Marchesi, 1961).
Molecular events that regulate diapedesis
Both vascular changes and intercellular adhesion interactions contribute
to the process of extravasation of leukocytes. In normal conditions of blood
flow, hydrodynamic forces keep the leukocytes in the center of the stream
(Goldsmith and Spain, 1984; Nobis et al.,1985). In inflammation, release of
mediators leads to vasodilation and a slowing of blood flow and an increase
in permeability. These factors act to force leukocytes to the edges of the flow,
near the vessel walls. By Pouseuille's law flow velocity is slower at the sides
than at the center of the stream, and thus a torque force is exerted on the
round leukocyte, contibuting to the rolling observed (Chien, 1982).
Adhesion of PMN to EC at sites of tissue injury or infection appears to
occur in two phases. PMN and endothelium initially increase their
adhesiveness within minutes, in a process independent of protein synthesis.
Then, over 1-2 hours from the onset of inflammation, new adhesion molecules
are synthesized and expressed on EC which can bind resting or activated PMN
(Osborn, 1990).
Adhesion molecules involved in diapedesis
Activation of cell adhesion molecules already present on the endothelial
cell surface contributes to the first phase of increased adhesiveness that leads
to extravasation. The best candidate for the molecule involved is GMP-140
(also known as PADGEM), a member of the LECCAM family of adhesion
5

molecules. L E C C A M s , also k n o w n as selectins, are transmembrane proteins
composed of three domains: a C-terminal region containing a variable number
of short consensus repeats found in complement regulatory proteins, an
epidermal growth factor-like region and an N-terminal lectin-like domain that
appears to be involved in adhesion (Springer, 1990). GMP-140 binds PMN
when exocytosed from platelet secretory granules (Larsen et al.,1989) and fixed
PMN can bind GMP-140-coated plastic surfaces (Geng et al.,1990). GMP-140
is released from the Weibel-Palade bodies of EC in culture within 5 minutes
after treatment with thrombin (Hattori et al.,1989) and mAb to GMP-140 block
binding of resting PMN to EC stimulated with histamine for 30 minutes
(Geng et al.,1990). These data imply that resting PMN could be recruited
within a few minutes of release of fast-acting inflammatory mediators such as
histamine, and the highly responsive PMN could then be activated by
subsequent mediators.
Seconds after exposure to a variety of substances, including TNFa,
leukotrienes, platelet activating factor and complement fragment C5a, PMN
exhibit a marked increase in adhesivity for EC and other substrates. This
protein synthesis-independent increase in adhesion is due primarily to
transient activation of the leukocyte integrins LFA-1 and CR3 (figure 2).
Several lines of evidence suggest a key role for the leukocyte integrins in
diapedesis. A variety of studies have demonstrated that antibodies against the
CD18 molecule block the inflammatory process both in in vitro and animal
model systems (Hernandez et al.,1987; Simpson et al.,1988; Vedder et al.,1988;
6

LFA-1
CDIIa/CD18

CR3
CDIIb/CD18

PI 50,95
CD1IC/CD18

Figure 2. Schematic representation of the three members of the leukocyte
integrin family.
Leukocytes integrins, also known as the CD11/CD18 family, are ap
heterodimers. The a chains of the family are represented by the corresponding
character and illustrate the differences in molecular weight between CDlla,
CDllb and CDllc (190 kD, 185 k D abd 150 kD, respectively). The P chains
(CD18) are identical and have a molecular weight of 95 kD. Both the a and
P chains are transmembrane proteins with small cytoplasmic domains.
(from Detmers and Wright, 1988)
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T u o m a n e n et al.,1989). Also, patients with a disease k n o w n as leukocyte
adhesion deficiency (LAD) (Anderson and Springer, 1987; Todd and Freyer,
1988) have a defect in the gene encoding the CD18 molecule which prevents
the expression of the leukocyte integrins. As a result, the patients suffer from
recurrent life-threatening infections with gram-positive, gram-negative and
fungal pathogens, and die at a young age. They exhibit extreme leukocytosis
and fail to form pus at sites of infection. In vitro experiments show PMN
from LAD patients are unable to adhere to C3bi-coated particles (Wright et
al.,1989), to protein-coated glass or plastic surfaces (Anderson et al.,1984) and
to endothelial cells (Harlan et al.,1985). The susceptibility of LAD patients to
infection is due to their inability to bind and ingest opsonized pathogens and
their failure to recruit cells to inflammatory sites. Leukocytosis results from
the failure of LAD phagocytes to extravasate, due to the inability to bind to
EC.
Leukocyte integrins are a subfamily of a large group of receptors termed
integrins (Table I)(Hynes, 1987; Albelda and Buck, 1990). Integrins are all ap
heterodimers involved in cell-cell or cell-extracellular matrix adhesion events.
Most integrins can be categorized into three subfamilies, determined by
whether they contain plx p2 or p3 respectively, although new oc's and p's that
fall outside these categories are being discovered. Every integrin requires
warm temperatures and divalent cations for binding and some recognize a
common tripeptide sequence, arg-gly-asp (RGD) on their ligands. The
leukocyte integrins are a group of three receptors that share a common p chain
8

The inUgrin receptor family

ff Subfamilies

Chicken integrin band 3
Fibronectin receptor 0
V L A - 0 (CD29)
Platelet glycoprotein lla
(ref* 1-4,8.15, 20-24)

Ligands
a,
a,
a,
a*

-

VLA-1
VLA-2
VLA-3
VLA-4

(CD49a)
(CD49b) platelet G P la
(CD49c)
(CD49d)

a, - VLA-5 (CD49«) platelet G P Ic
a, - VLA-6 (CD49Q platelet G P Ic
a, - CD51

L M (COL)
C O L (LM)
FN, LM, C O L
FN (alt)
V-CAM
FN

LM
FN
I-CAM

LFA-1 /Mac-1 /pi50,95 0
(CD18)
(refs 1, 2, 26, 27, 44)

a L - LFA-1 (CD lla)
a M - MAC-1 (CD lib)
a. - a chain of pi50,95 (CDllc)

C3bi, FB
C3bi?

3S Platelet glycoprotein IIIA
Vitronectin receptor /S (CD<51)
(ref 3, 7)

a[lb - platelet GPIIb (CD41)
a, - vitronectin receptor (CD51)

FB, FN, VN, V W F
VN, FB, VWF, TSP

J. (ref 14)

ctf

3S (ref 6)

av (CD51/CD?) [on epithelial cells and
some carcinomas]

3,

( C D 4 9 C C D ' ) [on epithelial cells]

LM?
VN, FN (Not FB)

•Abbreviations: L M , laminin; C O L , collagen; F N ;fibronectin;alt, alternatively spliced region; ic3b, breakdown product of the third
component of complement; FB, fibrogen, V N , vitronectin; V W F , von Willebrand's factor; T S P , thrombospondin.

Table I. (from Albelda and Buck, 1990)
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(p2 or CD18) and highly homologous, but distinct, a chains (CDlla, CDllb
and CDllc, figure 2). The differences among the a chains confer distinct

ligand binding specificities to the three members of this receptor subfami
The second pathway for adhesion of PMN to EC recruits PMN to tissues
within a few hours of the original inflammatory stimulus. Inflammatory

cytokines such as IL1 and TNFa induce expression of two adhesion molecules
on EC that bind PMN, ELAM-1 and ICAM-1 (Pober et al.,1986; Bevilacqua et
al.,1987; Dustin and Springer, 1988). ICAM-1 is a member of the Ig
superfamily of adhesion molecules that can bind LFA-1 and CR3 on PMN

(Marlin and Springer, 1987; Staunton et al.,1988; Diamond et al.,1990). ELA
1 is a LECCAM that can bind a ligand on the surface of PMN and act as a

"tethered chemoattractant", activating CR3 on PMN (Lo et al.,1991). Under i

vitro conditions of shear stress simulating venous flow conditions, integr
independent adhesion of PMN to IL1-treated EC withstands higher shear

stresses than integrin mediated adhesion (Lawrence et al.,1990; Lawrence a
Springer, 1991). LAD or anti-CD18-treated cells, that bind to EC through

adhesion mechanisms other than integrins, fail to undergo transendothelial

migration, consistent with the absence of neutrophil extravasation in leuk
adhesion deficiency (Smith et al.,1988). These data suggest the existence
adhesion cascade, in which LECCAMs capture PMN and trigger integrinmediated transmigration.
CR3 on PMN is regulated
The focus of the work presented here is a particular leukocyte integrin
10

k n o w n as complement receptor type 3, or C R 3 (also k n o w n as M o l , Mac-1 or
CDllb/CD18). CR3 binds several ligands, including fibrinogen, C3bi (a
cleavage product of the third component of complement), various microbial
surface antigens, and ICAM-1 and an as yet uncharacterized ligand on EC
(Wright et al.,1990; Diamond et al.,1990); the latter interactions occur in
diapedesis.
In the absence of an inflammatory stimulus, the adhesive mechanisms
involved in diapedesis are not needed. These adhesion interactions must
therefore be regulated. As noted earlier, the endothelium controls ELAM-1dependent adhesion by fusing Weibel-Palade bodies with the plasma
membrane in response to inflammatory stimuli (Hattori et al.,1989). In
contrast, CR3 is not regulated by PMN simply by changes in levels of
expression (Buyon et al.,1988; Philips et al.,1988; Vedder and Harlan, 1988; Lo
et al.,1989). In circulating, resting PMN, CR3 binds poorly to EC3bi (Wright
and Meyer, 1986) fibrinogen-coated substrates (Wright et al.,1988) or
endothelium (Lo et al.,1989). In order for CR3 to play a role in diapedesis, it
must be activated. Circulating PMN exposed to inflammatory mediators
increase the adhesivity of CR3, bind to EC via CR3 and then must release their
hold on the EC in order to make their way through the vessel wall.
The interaction of CR3 with its ligands is regulated (figure 3) (Wright
and Meyer, 1986; Lo et al.,1989). Resting PMN bind C3bi poorly, but when
PMN are treated with an agonist such as phorbol myristate acetate (PMA),
there is a rapid, transient increase in the extent of C3bi binding (left panel).
11
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Figure 3. CR3 binds ligand in a regulated manner.
P M N treated with phorbol esters exhibit a transient rise in CR3-mediated
binding to C3bi (left panel) and endothelium (right panel).
(from Wright and Meyer, 1986; Lo et al., 1989a)

12

This transient increase in C R 3 binding in P M N treated with phorbol ester is
true for another ligand of CR3, the endothelium (right panel). The transient
nature of this response to agonist appears necessary to allow the cell to cross
the endothelial barrier. A moving cell must adhere to the substrate at the
leading edge but also needs to detach its uropod for locomotion to occur. The
loss of avidity of CR3 may allow detachment of the uropod and reutilization
of receptors for a new round of adhesion.
The ability of CR3 to bind fibrinogen is also transiently enhanced by
treatment with agonists (see chapter 5). Other agonists of PMN, such as tumor
necrosis factor (TNF), C5a, formylated peptides, and NAP-1/IL8, can also
trigger a transient increase in the ability of CR3 to bind its ligands (Lo et
al.,1989; Detmers et al.,1990; SD Wright, unpublished observations). The
classes of molecules that can affect CR3 avidity on PMN has recently been
found to include surface-bound agonists. ELAM-1 on cytokine-treated EC can
increase CR3 avidity in PMN in contact with the endothelium (Lo et al.,1991),
and binding of LPS/LBP complexes to CD14 on the PMN can also trigger
increased CR3 binding to C3bi-coated particles (Wright et al.,1991).
Agonists that enhance the avidity of CR3 on PMN do cause a 2-3 fold
increase in CR3 expression due to exocytosis of specific granules, but this
increase in receptor expression is not the only mechanism contributing to the
change in CR3 function (5-10 fold) that occurs in response to these agonists.
PMN treated with the anion channel-blocking agent DIDS (4,4'dh^otMocyanostnbene-2,2'-disulfonic acid) do not degranulate in response to
13

normal stimuli. These cells, however, are capable of binding to cultured
endothelial cells in response to PMA, A23187, or fMLP in the absence of
upregulation of receptors on the cell surface (Vedder and Harlan, 1988). In
addition, cytoplasts, which are enucleated neutrophils depleted of specific
granules containing CR3, are also able to bind to endothelium (Vedder and
Harlan, 1988; Lo et al.,1989) or EC3bi (SD Wright, unpublished) although there
is no change in the expression of the receptor after stimulation with PMA,
A23187 or fMLP (Vedder and Harlan, 1988; Philips et al.,1988). Moreover,
blockade of cell surface CR3 with monoclonal antibody blocks CD18dependent aggregation of PMN despite the recruitment of new unblocked
receptors from intracellular pools (Buyon et al.,1988). Together these data
suggest that regulation of CR3 adhesivity is a qualitative rather than
quantitative change in the receptor. The molecular basis of this change in CR3
adhesivity has not been elucidated.
The work presented here was undertaken to determine the molecular
mechanism by which CR3 function is regulated.
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Chapter 2 - Materials and Methods
Buffers
Phosphate buffered saline (PBS) contains 137 mM NaCl, 2.7 mM KC1, 0.9 mM
CaCl2, 0.5 mM MgC^, and 8 mM phosphate pH 7.4; PD is PBS deficient in
Ca++ and Mg++ ions; HAP is PBS containing 0.5 mg/ml human serum
albumin, 3 mM glucose and 0.3 U/ml aprotinin; DGVB++ is 2.5 mM veronal
buffer pH 7.5 containing 75 mM NaCl, 2.5% glucose, 0.05% gelatin, 0.15 mM
CaCl2 and 0.5 mM MgCl2.
Monoclonal antibodies
mAbs OKM1 (IgG2b) and OKM10 (IgG2b), directed against the a chain
(CDllb) of CR3 (Wright et al.,1983) were a gift of Dr. G. Goldstein (Ortho
Pharmaceutical, Raritan, NJ); mAb 44 (clone aacf) against CDllb (Dana et
al.,1986), was provided by Dr. R. F. Todd III (U of Michigan, Ann Arbor, MI);
mAb TS1/22 (IgGl) directed against the a chain (CDlla) of LFA-1

(Sanchez-Madrid et al.,1982) was a gift of Dr. T. Springer (Dana-Farber Cance
Institute, Boston, MA); mAb LeuM5 (IgG2b) directed against the a chain
(CDllc) of pl50,95 (Lanier et al.,1985) was a gift of Dr. L. Lanier (Becton
Dickinson & Co., Mountain View, CA); AHB2 against integrin fa chain (Brown
et al.,1989) was provided by Dr. C. Damsky (UCSF, San Francisco, CA); mAb
IB4 (IgG2a) directed against the p chain (CD18) of CR3, LFA-1 and pl50,95

was as described (Wright et al.,1983); mAb 3G8 (IgGl) directed against the lo

avidity Fey receptor of neutrophils (FcRIII, CD16) was as described (Fleit et
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al.,1982); W 6 / 3 2 against class I histocompatability antigens (Barnstable et
al.,1978) was from the American Tissue Type Culture Collection (Rockville,
MD); LB-2 against ICAM-1 (Patarroyo et al.,1987) was a gift of Dr. E. Clark
(Seattle, WA); C3-9 directed against the third component of complement (Hack
et al.,1988) was a gift of Dr. E. Hack (University of Amsterdam, The
Netherlands); FITC-conjugated PAC-1 against activated gpHb/IIIa (Shattil et
al.,1985) was kindly provided by Dr. S. Shattil (U of Pennsylvania,
Philadelphia, PA) and FITC-conjugated goat anti-mouse IgG was from
HyClone Laboratories.
Cells
PMN were purified from fresh human blood on Ficoll-Hypaque gradients
(English and Anderson, 1974) and suspended in HAP buffer; THP-1A cells, a
monocytoid cell line, are as described (Auwerx, 1991), SCHU cells are an EBV
transformed B lymphoblastoid cell line kindly provided by Dr. S. Y. Yang
(Memorial Sloan-Kettering, NYC) that grow in suspension in RPMI with 10%
fetal calf serum and 0.1% penicillin /streptomycin; human monocytes and
lymphocytes were purified from buffy coats (Greater New York Blood Center)
on Percoll gradients. Monocytes were cultured in 12.5% human serum in
Teflon beakers as previously described (Wright and Silverstein, 1982). Upon
cultivation for 4-10 days, the cells matured into macrophages. Alternatively,
lymphocytes were purified from the mononuclear cell band on Ficoll-Hypaque
gradients by removing monocytes with a plastic adherence step (2 hours,
37°C).
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Extraction of IMF-1
A pellet of resting or stimulated whole PMN was resuspended by stirring,
vortexing and, on occasion, sonication, into
chloroform:methanol:water=10:10:l, at a concentration of at most 2.5 x IO8
PMN/ml. After stirring for a minimum of 36 hours, with at least 3 solvent
changes, supernatants were pooled and dried down under vacuum in a rotary
evaporator. The dried extract was resuspended in 3 bed volumes of
chloroform:methanol:water = 30:60:8, and passed through a DEAE-Sephadex
(Pharmacia) column. A column of 2-20 ml in volume was used for starting
material from IO9 -1010 cells, respectively .The column was then washed with
6 bed volumes of solvent and eluted with at least 3 bed volumes of
chloroform:methanol:0.8 M sodium acetate = 30:60:8. The eluate was dried
down under vacuum and resuspended in distilled water to a volume of up to
1 ml for IO8 PMN of starting material. A Sep-Pak CI8 (Waters) cartridge or
a hand-packed column of about 10 ml of the Sep-Pak sorbent was used to
desalt material from IO9 - 1010 cells, respectively. The C18 column was
prewashed in methanol, chloroform:methanol = 2:1, and methanol: 1.6 M
sodium acetate = 1:1 before sample was applied in at least 3 bed volumes of
water. Salt was washed out by extensive rinsing of the column with water (>6
bed volumes) and the lipid extract was eluted with 2 bed volumes of methanol
and at least 6 bed volumes of chloroform:methanol = 1:1. The eluted material
was dried down and resuspended either in chloroform:methanol = 2:1 for

storage as a stock of partially purified IMF-1 or was additionally fractionated
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in a Folch partitioning step, in which IMF-1 activity separates to the saline
upper phase in equilibrium with a lower phase of chloroform:methanol = 2:1.
Unless otherwise stated, the IMF-1 used in these experiments was taken from
the partially purified stock resulting from the Sep Pak step. IMF-1, other
lipids, and agonists were all dissolved in PBS for application to cells or
isolated receptor. Control lipids represent the lipids extracted from resting
PMN and were used at comparable or greater numbers of cell equivalents of
lipid to the amount of IMF-1 used in the same experiment.
Less than 0.1% of IMF-1 activity was found in the flowthrough from the
DEAE and Sep-Pak columns. However, up to 50% of IMF-1 activity was lost
in the Folch cut. Since the activity was not recovered in the organic phase, it
is possible that the procedure destroys IMF-1 activity and therefore it is
usually ommitted from isolations of IMF-1. Total yield of IMF-1 ranged from
10-33% of the material initially found in the chloroform/methanol extract of
the cell pellet.
Rosetting assay
The ability of CR3 on PMN to bind ligand is measured using the rosetting
assay, as previously described (Wright and Meyer, 1986). Briefly, lipid extract
or agonists were added to adherent PMN (2 x IO6 /ml) at 37°C for varying
times, and the cells were washed. Under standard conditions for assaying
IMF-1 activity, lipids or lipid extracts were incubated with PMN for 15
minutes. Sheep erythrocytes bearing covalently attached C3bi (EC3bi) or some
other ligand for CR3, such as lipid IVa, a biosynthetic precursor of LPS
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(Wright and Silverstein, 1982; Wright and Jong, 1986), were then incubated
with the PMN for 15 minutes at 37°C. Unattached erythrocytes were washed
away and bound EC3bi were scored by phase contrast microscopy. The
attachment index is the number of erythrocytes bound per 100 PMN.
Rosetting was blocked by addition of mAbs (10 ug/ml) against CR3 or C3bi.
A unit of IMF-1 activity is defined as the amount of IMF-1 needed to
half-maximally activate 1.2 x IO5 PMN in this rosetting assay. IO7 PMN yield
3-10 units of activity in a typical IMF-1 extraction. This means that extract
from 8-25 PMN can half-maximally activate a single cell in a volume of one
nanoliter. Half-maximal binding is achieved with an IMF-1 concentration of
8.3 U/ml.
Lipid IVa, used to make IVa-coated erythrocytes, was a generous gift of
Dr. C. R. H. Raetz (Merck, Sharp and Dohme Research Laboratories, Rahway,
NJ). Isoprenoids tested for IMF-1 activity in the rosetting assay were kindly
provided by Dr. P. Low (Stockholm University, Sweden).
Affinity purification of CR3
The purification of CR3 will be described in detail elsewhere (JAG Van Strijp
and SD Wright, manuscript in preparation). Briefly, C3bi from human serum
was covalently bound to Sepharose beads through the action of the alternative
pathway of complement activation. SDS-PAGE and immunoblotting
confirmed that >95% of the deposited protein on the beads was C3bi. IO8
PMN were lysed in 2.5% octylglucoside, 20mM HEPES buffer pH 7.4
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containing 5 0 m M NaCl, I m M CaCl2,1 m M MgCl 2 ,1 m M M n C l 2 and 1 ug/ml
each of the protease inhibitors antipain, benzamidine, chymostatin, leupeptin,
and pepstatin A, 0.24 U/ml of aprotinin and 2 mM PMSF (lysis buffer). The
lysate was cleared by centrifugation and incubated with C3bi-coupled
Sepharose for 3 minutes at room temperature. Beads were washed extensively
with lysis buffer and CR3 was eluted with 10 mM EDTA. Purity of extracted
CR3 was assessed by SDS-PAGE and silver staining.
Assay of purified CR3
CR3 eluted from C3bi-Sepharose was diluted into lysis buffer without
detergent and Terasaki plate wells were coated with purified CR3 for one hour
at 4°C. Wells were washed extensively with PBS. The number of available
CR3 epitopes per um2 of well surface was determined by using iodinated
monoclonal antibody 44a, against CDllb. Various amounts of purified CR3
adsorbed to wells were washed with Dulbecco's PBS and IMF-1 was added in
PBS. After 30 minutes incubation at room temperature in the presence or
absence of IMF-1, wells were washed with PBS and EC3bi were added at
108/ml in the presence or absence of mAbs 44a or LeuM5 (50 ug/ml) and
incubated for 20 minutes at room temperature. The plate was inverted to
remove unattached erythrocytes and washed. Bound erythrocytes were scored
by phase contrast microscopy.
Binding of PMN to fibrinogen-coated surfaces
Surfaces were coated for 60 minutes with 1 mg/ml fibrinogen (depleted of
plasminogen, a generous gift of Dr. L. Ossowski, Mt. Sinai Medical Center,
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N Y C ) in P D . P M N were allowed to adhere to fibrinogen-coated surfaces at
37°C for varying times in the presence or absence of 42 U/ml of IMF-1,
partially purified from fNLLP treated cells.
Binding of PMN to endothelium
PMN (2 x 106/ml) were treated with or without IMF-1 (42 U/ml, isolated from
cells treated with fNLLP) for 15 minutes or for varying times at 37°C, washed,
and allowed to bind to unstimulated confluent human umbilical vein
endothelial monolayers for 15 minutes at 37°C, in the presence or absence of
mAbs (10 ug/ml). Nonadherent cells were then washed away and bound
cells were quantitated using phase contrast microscopy.
Aggregation of lymphocytes
Lymphocytes were purified on Percoll gradients as described (33), and
contaminating monocytes were removed by plastic adherence. Cells (106/ml)
were then added to Terasaki plate wells and PMA (100 ng/ml), IMF-1 (42
U/ml) or lipids extracted from resting PMN ("control lipids", extracted from
3 times as many cells as the IMF-1) were added in the presence or absence of
antibodies (10 jig/ml). Cells were incubated 30 minutes at 37°C and
aggregation was determined by phase-contrast microscopy and reported as:
%aggregation = [l-(free cells per mm2 in test well/free cells per mm2 in
control untreated wells)! x 100.
Platelet aggregation and flow cytometry
Platelets were purified as described (Silverstein and Nachman, 1987). Briefly,
whole blood was centrifuged at 180g and the platelet fractions were gel
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filtered on Sepharose 2B. Aggregation of a solution of approximately 2 x 10 s
platelets/ml in modified Tyrode's buffer containing up to 200 ug/ml
fibrinogen and 1 mM MgCl2 was monitored in a Pay ton platelet aggregometer
set at 37°C under stirring conditions. IMF-1 up to 100 U/ml was tested, and
compared to 3 U/ml thrombin as control. As a control, aggregation of
platelets to very low concentrations of thrombin (0.018 U/ml) was shown to
be fibrinogen dependent. For flow cytometry studies, IO6 platelets were
incubated for 15' at 20°C with FITC-conjugated anti-ccIIb (PAC1, 40 ug/ml) in
the presence of IMF-1 (50 U/ml), lipid extracts lacking IMF-1, or thrombin (0.2
U/ml).
Adhesion of lymphocytes to fibronectin
Terasaki wells were coated with fibronectin (100 ug/ml, Greater New York
Blood Center) for 60', 20°C, washed and cells were added for 30', 0°C, in the
presence or absence of Ab (10 ug/ml or neat hybridoma supernatant). PMA
(30 ng/ml) or IMF-1 (42 U/ml) were added for 10', 37°C. Nonadherent cells
were washed away and remaining cells counted.
Reverse phase chromatography
A Waters uBondaPak C18 reverse phase column (10 um particle size, 3.9mm
x 150mm) was loaded with IMF-1 (50 units, partially purified from fNLLP
treated cells), LTB4 (5 ng, and 0.5uCi) or LXA4 (5 ug) and eluted with a 1% per
minute gradient of water to acetonitrile. IMF-1 elution was monitored by
testing fractions in the rosetting assay, LTB4 by cpm per fraction and LXA4 by
absorbance at 254 nm. IMF-1 was dried down and resuspended in water and
22

loaded after a 5' spin at 10,000 g to remove insoluble material. A rosetting
assay on the material loaded revealed no depletion of IMF-1 activity upon
removal of particulates.
Size exclusion chromatography
IMF-1 (partially purified from fNLLP treated cells, or derived from column
fractions of a previous run) was separated on a TSK G2000HXL size exclusion
chromatography column (Supelco) run in tetrahydrofuran. IMF-1 was dried
down and resuspended into tetrahydrofuran, and loaded after a 5' spin at
10,000 g to remove insoluble material. This procedure did not deplete the
loaded material of IMF-1 activity, as determined by rosetting assay comparison
of the suspension before and after spinning. Elution volumes of polystyrene
molecular weight standards in the range of 1000 - 180 daltons were used to
generate a calibration curve. Linear regression yields a standard curve of y = 1.278x + 3.302 with r2=0.9884. IMF-1 activity of each fraction was determined
by rosetting assay.
Inhibitor studies
PMN treated with WEB 2086 (10 uM; 250, indomethacin (10 uM; 1000, MK886
(50, 5, 0.5 nM; 500, L651,392 (5, 0.5, 0.05 uM; 500 or bromophenacyl bromide
(30,3, 0.3 uM; +/- arachidonate 10,1, 0.1 uM; 700 were tested for their ability
to bind EC3bi in the rosetting assay with or without an incubation with PMA
(30 ng/ml, 200 or IMF-1 (42 U/ml, 200.
Lovastatin treatment in the rosetting assay
Lovastatin, a competitive inhibitor of the enzyme HMGCoA reductase, was
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kindly provided by Dr. Alberts (Merck Sharpe and D o h m e Research
Laboratories, Rahway, NJ) and was base treated to open the lactone ring as
follows: 16 mg/ml lovastatin in 40% ethanol containing 60 mM NaOH was
heated to 50°C for 2 hours, neutralized with HC1 and diluted to a 4 mg/ml
stock with H20 (final concentration of ethanol in stock was 10%). Lovastatin
(40 ug/ml in PBS), was added to adherent PMN for 90 minutes at 37oC in the
presence or absence of mevalonate (50 ng/ml in PBS) to overcome the block.
After 10 minutes in lovastatin, C5a (10"8M in PBS) was added and after 70
minutes in lovastatin, PMA (30 ng/ml in PBS) or IMF-1 (42 U/ml) was added.
After 75 minutes in lovastatin, EC3bi were added for 15 minutes and the
attachment index was measured.
Mevalonate labeling
500 uCi R,S-[5-3H(N)]-Mevalonate (40 Ci/mmol, New England Nuclear) and
80 ug lovastatin were dried down in a glass 12 x 75 mm tube and 2 x IO8
PMN were added in 0.5 ml HAP buffer. After 20' at 37°C, C5a (Dr. M.
Springer, Merck, Sharp & Dohme Research Laboratories, Rahway, N.J.) was
added to 10"8M final concentration. After another 1 hour and 40 minutes at
37°C, TNF was added to a final concentration of 5 x IO3 U/ml and incubated
at 37°C for 15'. Cells were spun out and resuspended in about 5 ml of
chloroform:methanol:water=10:10:l. After a total of 24 hours of stirring with
2 solvent changes, extracts were pooled and half was dried down and
resuspended in 20% CH3CN (aq) and run on the Waters C18 reverse phase
column as described. 11.35% of the counts added were incorporated into the
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cells.

For the chromatography step, 1 0 % of the counts were lost to

precipitation after dissolving in 20% CH3CN (aq).
Gas Chromatography / Mass Spectroscopy
70,000 units of partially purified IMF-1 was purified on a C18 Waters
uBondapak reverse phase column (lOum particle size, 3.9mm x 150 mm) in a
1% per minute gradient of 20 - 60% acetonitrile (aq). Elution of IMF-1 at 47%
CH3CN was verified by testing column fractions by rosetting assay. Purified
IMF-1, as well as material from fractions eluting just before and after those
containing IMF-1 activity, was derivatized with trimethylsilane (or deuterated
TMS) using 1:1=BSTFA (bis-trimethylsilyltrifluoroacetamide, or BSTFAdl8):pyridine, 50°C, 30' and loaded onto a capillary gas chromatography
column (J&W DB-5-30W, 15m) in series with a Finnigan-MAT TSQ70B (triple
quadrupole) mass spectrometer in electron impact (EI, 70ev) ionization mode.
The sample was eluted from the GC column by the following temperature
ramp: initial temperature 70°C hold for 2 minutes, ramp to 300°C at
10°/minute, hold for 1 minute. The mass spectrometer was scanned from 40
to 800°C every second. The samples were also run underivatized or as silyl
derivatives by direct probe in both the EI and fast atom bombardment (FAB)
ionization mode, but no peak corresponding to the 315 species was observed.
All data was analyzed using the ICIS data system.
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Chapter 3 - Discovery of a molecule that can activate
complement receptor type 3
The IMF-1 hypothesis
Agonists stimulate PMN and lead to a variety of effects, including
degranulation, Ca+2 transients, generation of the oxidative burst and a
transient increase in the avidity of CR3. A homologous receptor, an integrin
which recognizes vitronectin (avp3), was found to colocalize with gangliosides
GD2 and GD3 in adhesion plaques on the melanocyte membrane, suggesting
that integrin function may be regulated by an association with lipids (Cheresh
et al.,1987). The work presented here was undertaken to determine whether
a lipid may be responsible for regulating the avidity of CR3. The data are
consistent with the following hypothesis. PMN stimulated with agonists
would rapidly produce a specific lipid, called integrin modulating factor-1, or
IMF-1, from a putative precursor (figure 4). Alternatively, this lipid may be
sequestered in a resting PMN and released upon activation. IMF-1 would
bind directly to CR3 or perhaps alter the microenvironment of the receptors,
inducing receptor clustering, resulting in an increased ability of the receptor
to bind ligand. Activation of the receptor is transient: IMF-1 may be degraded
by some cellular enzyme or inactivated by binding to an inhibitor, or
otherwise sequestered. Thus it is proposed that the ability of CR3 to bind
ligand is regulated by a lipid, IMF-1, produced by PMN upon stimulation with
agonist, that acts as an allosteric activator of the receptor.
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agonist

Figure 4. T h e IMF-1 hypothesis.
Agonists interact with specific surface receptors on P M N , triggering
intracellular signals that lead to a variety of effects, including C a + + transients,
generation of the oxidative burst and a transient rise in adhesivity mediated
by C R 3 . The latter response m a y be due to production of a lipid, IMF-1, from
a specific precursor, pre-IMF-1. W h e n present in the cell, IMF-1 would interact
directly with C R 3 to increase the receptor's ability to bind ligand.

27

The preceding hypothesis suggests three testable predictions: 1) addition

of IMF-1 to unstimulated PMN should cause an increase in CR3 binding t
ligand; 2) IMF-1 should only be found in stimulated, and not resting,

and 3) IMF-1 should be able to bind directly to isolated CR3 and alter
avidity for ligand.
IMF-1 increases binding of PMN to EC3bi
To test whether IMF-1 can cause increased binding of CR3 to ligand,
PMN were stimulated with PMA and lipids were extracted from the cells

chloroform/methanol. The acidic lipids were extracted from this mixtur

anion exchange chromatography and sonicated into aqueous buffer. Addit

of this partially purified lipid extract to resting PMN caused a dose-

rise in their ability to bind EC3bi (figure 5a, squares). Binding of CR

is measured in a rosetting assay, involving the interaction of adheren

and C3bi-coated sheep erythrocytes (EC3bi) to form rosette-like struct

can be quantitated by an attachment index, which is the number of EC3b

bound per 100 PMN, as determined by phase contrast microscopy. Increas

binding of PMN treated with lipid extract to EC3bi was mediated by CR3
because binding could be blocked with mAbs against CR3 a or p chain

(OKM10, IB4), as well as mAb against C3 (mAb C39), while a non-blocking

anti-a chain mAb (OKM1) had no effect (Table II). The partially purifi

extract acts specifically on CR3 because binding of erythrocytes coate

IgG, mediated by Fc receptors, was unaffected in PMN exposed to the ext

(fig 5a, open triangles). These observations indicate that the partiall
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Figure 5. IMF-1 increases CR3-mediated binding to C3bi-coated erythrocytes
in a time- and dose-dependent manner
panel A . Dose-dependence.
Partially purified IMF-1 (from cells treated with P M A , 20') was prepared
at various dilutions and applied to resting adherent P M N for 15 minutes at
37°C. The ability of IMF-1-treated cells to bind EC3bi (squares) was measured
in the rosetting assay (see Materials and Methods). Lipids extracted from
unstimulated P M N (solid triangles) had no effect on C R 3 activity at any
dilution. IMF-1 in the lipid extract had n o effect on binding of erythrocytes
coated with IgG (open triangles).
panel B. Time course.
Partially purified lipids from P M N treated with the chemotactic peptide
fNLLP for 15' (42 units/ml IMF-1 activity) were added to adherent P M N and
after various intervals, C R 3 activity was measured by the rosetting assay.
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lipid extract from activated P M N contains a factor, IMF-1, that can change the
binding activity of CR3. A unit of IMF-1 is defined as the amount needed to
achieve half-maximal binding of EC3bi to 1.2 x IO5 PMN under standard assay
conditions. In this experiment, dilution of lipid extract from 107 PMN by
1/360, to a final volume of 120 ul (standard volume), yields one unit. One
unit in 120 ul is equivalent to 8.3 U/ml. In the IMF-1 preparation used in

figure 5, IO7 cells were extracted to give 3 units of IMF-1. Typically, 3-10 u
of IMF-1 can be extracted from 107 stimulated PMN and the IMF-1 from 8-25
stimulated PMN is sufficient to half-maximally activate a single neutrophil.
The effect of IMF-1 on CR3 was transient. Enhanced binding of ligand
peaked at 20 minutes and fell in the subsequent 40 minutes (figure 5b). This
decline in CR3 activity may be due to degradation, sequestration or binding
of IMF-1 by an inhibitor. It is likely to be due to degradation of IMF-1,
because cells that were treated with IMF-1 for 60 minutes responded to
readdition of IMF-1 with kinetics and a magnitude of response similar to the
initial response (see figure 26).
Levels of IMF-1 correlate with the binding activity of CR3
IMF-1 can be extracted from PMN only upon activation, since it was not
found in lipids extracted from unstimulated PMN (figure 5a, solid triangles).
The amount of IMF-1 present in cells was detennined by stimulating PMN for
various intervals with PMA then measuring the amount of IMF-1 in extracts
of the cells (figure 6, triangles). Maximal amounts of IMF-1 were obtained
after 20 minutes of stimulation, but the amount of IMF-1 in stimulated cells
30

BINDING INDUCED BY IMF-1 IS INHIBITABLE BY ANTIBODIES
AGAINST CR3 AND C3bi

agonist

Ab

Ag

binding of EC3bi (Al)

none

none

16

LMF4
LMF-1
LMF-1
LMF-1
LMF-1

none

206
83
31
27
175

IB4
C39
OKM10

OKM1

CD18
C3
CDllb
CDllb

Table II. Partially purified IMF-1 (from PMA-treated cells, 42 units/ml) was
added to P M N in the rosetting assay in the presence or absence of various
monoclonal antibodies (10 ug/ml). This experiment is representative of three
repeats.
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Figure 6. IMF-1 content of P M N correlates with C R 3 activity.
Phorbol myristate acetate ( P M A , 30 ng/ml) w a s added to resting adherent
P M N for various times at 37°C, and washed away. Binding of C R 3 to O b i
w a s then measured (squares) in the rosetting assay. A parallel set of P M A treated P M N were extracted for lipids and the number of units of IMF-1
activity present in the extract from 10 7 P M N w a s determined (triangles) by
diluting the extract and measuring the amount needed to half-maximally
activate 1.2 x 10 5 P M N to bind EC3bi.
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declined to low levels by 40 minutes. The ability of C R 3 to bind EC3bi also

exhibits a transient rise and fall when assayed in a parallel population of cel
(figure 6, squares), suggesting that the capacity of CR3 to bind ligand may be
controlled by the cellular levels of IMF-1. This hypothesis was tested using
additional agonists of PMN. Tumor necrosis factor (TNF, 5 x IO3 U/ml, figure
7) and formyl-norleucyl-leucyl-phenylalanine (fNLLP, 5 x IO"8 M, figure 8)
each induced a transient rise in CR3 activity, and each caused a proportional
rise in the amount of IMF-1 extractable from the cells. These experiments also
revealed that IMF-1 could be extracted from PMN as quickly as 30 seconds
after stimulation with agonist and that at all times less than 2% of the IMF-1
could be found in the overlying medium (figure 7). Thus it appears that IMF1 remains in the cells that produce it and that it functions as an endogenous
regulator of cell function. IMF-1 derived from a mixture of cells treated with
PMA, TNF, fNLLP or platelet activating factor (PAF, 10"7 M, 150 migrates as
a single peak of activity on reverse phase chromatography and thus was
considered to be the same molecule and used interchangeably in the
experiments reported below.
IMF-1 interacts directly with purified CR3
CR3 was purified from a lysate of resting PMN by affinity
chromatography on C3bi-coated Sepharose beads. CR3 was eluted with
EDTA, the purity of the extracted CR3 was assessed by SDS-PAGE and silver
staining (figure 9), and then CR3 was adsorbed to culture wells. The resulting
CR3-coated surfaces bound EC3bi very poorly, but preincubation of the
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Figure 7. The majority of IMF-1 produced by activated P M N is cell
associated.
P M N were exposed to T N F (5 x IO3 u/ml) for varying times and spun down.
Pellets were extracted with chloroformrmethanol:water = 10:10:1 and
supernatants were dried d o w n in a rotary evaporator and resuspended into
chloroforrrumethanol = 2:1. The extracts were then tested for IMF-1 activity
by rosetting assay.
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Figure 8. IMF-1 can be produced by P M N within 30 seconds of stimulation.
P M N were exposed to fNLLP (5 x IO"8 M ) for varying times and spun down.
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supernatants were dried d o w n in a rotary evaporator and resuspended into
chlorofonrumethanol = 2:1. The extracts were then tested for IMF-1 activity
by rosetting assay.
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Figure 9. S D S - P A G E of purified CR3.
C R 3 was purified from resting P M N by affinity chromatography and run on
SDS-PAGE and silverstained. The two bands
correspond to the a chain at 185 k D and the p chain at 95 kD.
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adsorbed receptor with lipid extracts containing IMF-1 dramatically enhanced
the ability of CR3 to bind ligand (figure 10a). IMF-1 highly purified by C18
reverse phase chromatography (see figure 15), is equally capable of enhancing
binding of EC3bi to CR3 (table III) but lipids extracted from unstimulated
PMN, which lack IMF-1, could not increase the binding activity of isolated
CR3 (figure 10b, "ctrl lipids"). The IMF-1-induced enhancement of EC3bi
binding was dependent on the concentration of adsorbed CR3 (figure 10a) as
well as on the concentration of IMF-1 added (figure 11). The ability of IMF-1
to enhance binding of purified CR3 to C3bi was not transient because
preincubation of adsorbed CR3 for up to 60 minutes with IMF-1 resulted in
sustained high binding activity (figure 12). Several additional control
experiments indicate that IMF-1 acts by altering the avidity of CR3. The IMF-1
molecule itself did not bind to EC3bi since surfaces treated with IMF-1 alone
did not bind EC3bi (figure 10a), and preincubation of EC3bi with IMF-1 did
not alter the extent of binding of erythrocytes to receptor-bearing surfaces
(table IV). Furthermore, binding of EC3bi to purified CR3 could be blocked
by mAb directed against CR3 (figure 10b). Thus, IMF-1 altered the binding

activity of purified CR3 in the absence of other cellular factors and therefore
might directly affect the receptor. Since LMF-1 cannot change the number of
receptors present and is unlikely to change the two dimensional distribution
of the adsorbed CR3, IMF-1 may affect CR3 through an allosteric mechanism.
PMN could regulate CR3 binding to ligand by altering the relative
abundance of IMF-1. The data has borne out the predictions: 1) exogenous or
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Figure 10. IMF-1 interacts directly with C R 3 to increase binding to ligand.
Panel A. CR3-coated wells were incubated with EVLF-1 (165 U/ml) and the
binding of EC3bi to the coated surface was determined. Data is the average
of 3 experiments, performed in triplicate, bars show the SEM.
Panel B. Wells were coated with 33 C R 3 molecules per u m 2 (two bars at left)
or 87 C R 3 per u m 2 (four bars at right), incubated with IMF-1 or lipids
extracted from cells lacking IMF-1 ("ctrl lipids"), and washed. IMF-1-induced
binding of EC3bi to receptor was also measured in the presence of an antiCDllb antibody, 44a, or an anti-CDllc antibody, LeuM5, as a control. Both
antibodies were used at 50 ug/ml. Data is the average of 3 experiments,
performed in triplicate, bars show the SEM.
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PURIFIED IMF-1 INCREASES BINDING OF EC3bi TO PURIFIED CR3

CR3 preincubation

EC3bi bound per m m

CR3 (87/um2)

alone
+ control
+ purified IMF-1

280+56
240+56
1800+400

noCR3

+ purified IMF-1

160+112

Table III. 70,000 units of IMF-1 were fractionated by reverse phase
chromatography (see chapter 4). A 1 5 ul aliquot of a 2.5 m l fraction containing
IMF-1 activity was dried d o w n and resuspended to 20 ul in PBS. This purified
IMF-1 w a s applied to CR3-coated culture wells for 30 minutes at room
temperature. A similar aliquot from an immediately adjacent fraction, lacking
IMF-1 activity in the rosetting assay, w a s used as a control.
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Figure 11. IMF-1 increases binding of purified C R 3 to EC3bi in a dosedependent manner.
CR3-coated culture wells were incubated with varying amounts of
partially purified IMF-1 (isolated from fNLLP treated cells) in the purified
C R 3 assay (squares). Uncoated wells incubated with IMF-1 were unable to
mediate binding to EC3bi (triangles).
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Figure 12. The effect of IMF-1 on purified CR3 is time-dependent
CR3-coated wells (87 CR3/um 2 ) were incubated with IMF-1 (165 U/ml) for
varying times before binding to EC3bi was measured.

41

PREINCUBATION OF EC3bi WITH IMF-1 DOES NOT INCREASE BINDING TO CR3

EC3bi bound per m m 2
CR3(87/um2)

alone
+ IMF-1, 55 U/ml
+ IMF-1,165 U/ml

5760+2320
4160+1680
2640+1280

CR3 (33/um2)

alone
+ IMF-1, 55 U/ml
+ IMF-1,165 U/ml

1260+ 200
960+264
1000+ 272

Table IV. EC3bi (109/ml) were incubated with IMF-1 (isolated from fNLLP
treated cells) for 20 minutes at room temperature, washed extensively in
D G V B + + and resuspended to lOfymL EC3bi were then allowed to bind to CR3coated culture wells for 20 minutes at room temperature.

42

endogenous IMF-1 can increase C R 3 binding to ligand, 2) IMF-1 can be
extracted from PMN only after stimulation with agonists with a time course
that matches the transient enhancement of CR3 binding, and 3) IMF-1
regulates CR3 function by interacting directly with the receptor.
The remaining chapters will present the current state of knowledge of
the chemical properties of IMF-1 and will present more data on the biology of
IMF-1 function.
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Chapter 4 - The chemistry of IMF-1
Isolation of IMF-1
IMF-1 can be extracted from cell pellets using a modified ganglioside
purification scheme (see chapter 2). Briefly, lipids are extracted using
chloroform:methanol:water=10:10:l, and acidic lipids are purified from the
extract by anion exchange chromatography on DEAE sephadex, followed by
desalting with a C18 Sep Pak cartridge. For further purification, IMF-1 can be
separated from contaminants by a Folch partitioning step, in which IMF-1 and
other acidic lipids localize to the aqueous phase. Less than 0.1% of IMF-1
activity can be found in the flowthrough from the DEAE and Sep Pak
columns. Total yield of IMF-1 ranges from 10 to 33% of starting activity. IMF1 partitions to the butanol phase in a butanol:H20=l:l two phase system.
Based on solubility and chromatographic properties, IMF-1 is an acidic,
amphiphilic molecule. The preparation of lipids eluted from the Sep Pak
column will be referred to as the partially purified lipid extract, and this
material was used in the preceding biological characterization experiments on
IMF-1, unless otherwise specified.
IMF-1 is a single, small molecular species.

The partially purified lipid extract contains several acidic lipids, visible as
number of bands by thin layer chromatography (figure 13). To determine if

IMF-1 is a single species, the lipids were further fractionated on a C18 revers
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Figure 13. Thin layer chromatography of partially purified lipid extract
25 units of IMF-1 in a partially purified lipid extract from P M N treated
with P M A (lane 2) or extract from an equivalent number of unstimulated P M N
(lane 3) were spotted onto a high performance thin layer chromatography
silica gel 60 plate (E. Merck). Ganglioside controls were run in lanes 1 and 4.
The plate w a s developed in chloroform:methanol:0.2% CaCl 2 (aq)=55:45:10.
The plate w a s stained with iodine vapor and photographed immediately.

45

1 2
GM3
GMi

GTib-

3

4

= GM2
— GDla

phase column (figures 14 and 15). IMF-1 eluted as a single peak of activity at
approximately 50% acetonitrile, that did not correspond with any peak of
absorbance.
Ultraviolet and visible spectroscopy.
An ultraviolet and visible spectrum of IMF-1 purified on the C18 reverse
phase column is shown in figure 16, left panel. The solvent blank is shown at
right. IMF-1 has a A^^ at 196 nm with a slight shoulder out to 300 nm. The
spectrum was flat between 300 and 800 nm. This result suggests that IMF-1
does not contain peptide bonds, which absorb at 214 nm, nucleic acids, which
absorb at 260 nm, or conjugated double bond systems, which absorb at
wavelengths over 300 nm. Since the amount and extinction coefficient of IMF1 is unknown, it is possible that there was insufficient material present to
produce a characteristic absorbance peak. The very large amount of
bioactivity present in the sample and the appearance of a peak at 196 nm
argues against this interpretation.
The fine discrirnination achievable by reverse phase chromatography,
coupled with the apparent purity of material suggested by the simple and
uncluttered UV spectrum, argue for a high degree of purity of the IMF-1
prepared by reverse phase chromatography.
None of a wide spectrum of lipids have IMF-1 activity.
In an effort to identify IMF-1, many well characterized lipids were tested
for IMF-1 activity in the rosetting assay. Table V lists those tested, none of
which were able to enhance rosetting of PMN to EC3bi.
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Figure 14. C^g reverse phase chromatography of IMF-1, L T B 4 and LXA 4 .
A Waters uBondaPak C 1 8 reverse phase column (10 u m particle size, 3.9mm
x 150mm) was loaded with IMF-1 (50 units, partially purified from fNLLP
treated cells), L T B 4 (5 ng, and 0.5uCi) or L X A 4 (5 ug) and eluted with a 1 % per
minute gradient of water to acetonitrile (solid line). The dotted fine
corresponds to the chromatogram for the L X A 4 run, A ^ . IMF-1 elution was
monitored by rosetting assay (histogram), L T B 4 by c p m per fraction (dashed
line) and L X A 4 by absorbance at 254 n m (dotted line).
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Figure 15. Cjg reverse phase chromatography of IMF-1 and LXA 4 .
A Waters uBondaPak C 1 8 reverse phase column (10 u m particle size, 3.9mm
x 150mm) was loaded with IMF-1 (50 units, partially purified from fNLLP
treated cells) or L X A 4 (5 ug) and eluted with a 1 % per minute gradient of
water to acetonitrile (solid line). The dotted line corresponds to the
chromatogram for the L X A 4 run, A 2 5 4 . The dashed line represents the
chromatogram for the IMF-1 run, A ^ . IMF-1 activity was monitored by
rosetting assay (histogram).
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Figure 16. Ultraviolet and visible spectrum of purified IMF-1.
A Perkin-Elmer Lambda 5 UV/Vis Spectrophotometer, equipped with a
double b e a m and matched quartz cuvettes, w a s zeroed with acetonitrile in
both cells (at right) and then IMF-1 purified by reverse phase chromatography
(52,000 u / m l in acetonitrile) was added to one cell and a spectrum obtained
(at left).

49

N O N E OF THE FOLLOWING

at 100 pg/ml:
G M 1 , asialo G M 1
G M 2 , asialo G M 2
GM3
GDla, GDlb
GD2, G D 3
GTlb
iactosylceramide
globoside
sulfa tide
bovine brain
gangliosides
at 15,1.5, 0.15 ug/ml:
geranyl pyrophosphate

HAVE IMF-1 ACTIVITY IN THE ROSETTING ASSAY.

at 50, 5 and 0.5 ug/ml:
GQlb
PC, dimyristoyl P C
myristic anhydride
phosphatide acid:
dilauroyl, dimyristoyl,
dioleoyl
lysophosphatidic acid
myoinositol bis phosphate
lysophosphatidylinositol
dimyristoyl phosphatidyl
glycerol
dolichol monophosphate
dimethyl sphingosine
at 3,1.5, 03 pg/ml:

at 03, 0.03, 0.003 ug/ml:
9-hydroxy linoleic acid
13-hydroxy linoleic acid
at 50, 5, 0.5 uM:
farnesol
farnesyl pyrophosphate
cis geranylgeraniol
cis geranylgeranyl
pyrophosphate
trans geranylgeraniol
trans geranylgeranyl
pyrophosphate
solanisol
solanisyl phosphate
solanisyl pyrophosphate

sphingosine

Table V. The lipids listed were dissolved in PBS, sonicated, and incubated
with P M N for 15 minutes in the rosetting assay.
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It is possible that the P M A used to activate the extracted P M N m a y be

a contaminant in the partially purified lipid extract and is responsible for IMF1 activity. Several pieces of evidence indicate that this is not the case. PMA
is not anionic and appears in the flow through of the anion exchange column,
rather than cofractionating with IMF-1 in the eluate. PMA is sensitive to
hydrolysis in water and the extract is in aqueous solution for a minimum of
12 hours during the purification. Purification of EMF-1 from cells treated with
[3H1-PMA yields only background levels of radioactivity in the IMF-1
fractions. These represent at most 0.03 ng/ml of potential contaminating
PMA. This concentration is three orders of magnitude less than normally
added to cells and 100 times less than the minimum needed to activate
phagocytosis in macrophages (Wright and Silverstein, 1982). Finally, and most
convincingly, treatment of PMN with a variety of agonists other than PMA,
both lipids and proteins, all result in IMF-1 production. IMF-1 is produced by
PMN stimulated with tumor necrosis factor (TNF, 5 x IO3 u/ml, 150, platelet
activating factor (PAF, 100 nM, 150 and formyl-norLeu-Leu-Phe (fNLLP, 5 x
10'8M, 5-150 as well as by PMN stimulated with PMA (30 ng/ml, 200. The
native conformation of proteins can be completely disrupted by exposure to
organic solvents. Tumor necrosis factor, for example, would be unable to
maintain its active configuration after extraction in chloroform/methanol, and
so is unlikely to be a contaminant responsible for the CR3 modulating activity
in the extract.
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Platelet activating factor (PAF) is another potential contaminant in the
lipid extract that may account for IMF-1 activity. PAF, or L-ccphosphatidylcholine, p-acetyl-y-O-alkyl, is a lipid produced by PMN in
response to agonists (Baggiolini et al.,1988), that can increase CR3 binding
activity. To rule out that IMF-1 is equivalent to PAF, a PAF receptor
antagonist, WEB 2086 (Casals-Stenzel et al.,1987), was added at concentrations
that completely block 100 nM PAF-induced rosetting of EC3bi. The antagonist
had no effect on IMF-1-induced rosetting (table VI).
LPS is yet another potential contaminant of the IMF-1 preparation, since
it is often found contaminating laboratory solutions and glassware. Unlike
LPS, IMF-1 (42 units/ml) does not cause TNF production in whole blood,
suggesting IMF-1 activity is not due to contaminating LPS and suggesting that
IMF-1 does not function similarly to LPS (figure 17).
IMF-1 is resistant to a variety of chemical modifications.
Classes of compounds with physical properties similar to those of IMF-1
include glycerol- or sphingosine-based lipids, eicosanoids, other fatty acids,
isoprenoid lipids and proteins or peptides with a hydrophobic tail. All but
isoprenoids were ruled out by subjecting IMF-1 to treatments that destroy
particular classes.
In all cases, phosphatidylcholine (5 ug), GM1 (5 ug) or some other lipid
containing a susceptible linkage was cleaved in parallel with IMF-1.
Quantitative destruction of this control compound was verified by thin layer
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chromatography comparison with a m o c k treated control. The details of the
treatments are outlined in table VII and summarized below and in figure 18.
IMF-1 retained activity when treated with base (30% ammonium
hydroxide or IN NaOH) or acetic anhydride, suggesting it does not contain
ester-linked fatty acids or a phosphate base. IMF-1 was not affected by
desialylation with acetic acid or by neuraminidase, suggesting IMF-1 activity
does not reside in a ganglioside. Acid hydrolysis (2N or 0.5N methanolic HC1)
did not destroy activity, so IMF-1 does not have a sphingosine or glycerol
backbone, or glycosidic bonds that are needed for activity. IMF-1 activity is
unaffected by phosphatase, hydrofluoric acid or protease, suggesting that
phosphate groups are not essential for activity and and that IMF-1 does not
have a protein structure. In addition, reduction with sodium borohydride,
oxidation with hydrogen peroxide, and periodate oxidation of vicinal
hydroxyls all had no effect on IMF-1 activity. Resistance to nitrous acid
deamination suggests IMF-1 does not contain primary amines. Of the original
categories of candidate structures for IMF-1, the only ones that would remain
unaffected by these treatments are isoprenoids, prostaglandins and fatty acids.
A protease-resistant peptide with a lipid tail is not a good candidate because
IMF-1 does not absorb at 214 nm, the wavelength of absorption of the peptide
bond. Prostaglandins and conventional fatty acids are unlikely considering
IMF-1 activity partitions to the aqueous phase rather than the organic in a
Folch partition, and since prostaglandins contain conjugated double bond
systems, ruled out by the spectrograph.
53

IMF-1 ACTIVITY IS NOT DUE TO EXTRACTED PLATELET ACTIVATING FACTOR.

agonist inhibitor EC3bi (Al)
none none 112

PAF, 100 n M
PAF, 100 n M

none
W E B 2086, lOuM

370
106

PAF,lnM
PAF,lnM

none
W E B 2086, lOuM

312
169

IMF-1, 42 u/ml
IMF-1,42 u/ml

none
W E B 2086, lOuM

652
575

Table VI. P M N were treated with P A F or IMF-1 for 15' in the rosetting assay
in the presence or absence of the P A F antagonist, W E B 2086. Cells were
washed and allowed to interact with EC3bi.
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4i LPS alone (•)
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Figure 17. IMF-1 does not contain or act like LPS.
Whole blood was incubated for 5 hours at 37°C with lipopolysaccharide (LPS),
IMF-1 (42 units/ml) or both. After spinning out the cells, supernatants were
tested for the presence of tumor necrosis factor (TNF) by radioimmunoassay
(Vlassara, et al.„ 1988). This experiment is representative of two repeats.

55

IMF-1 ACTIVITY IS UNAFFECTED BY A VARIETY OF CHEMICAL AND
ENZYMATIC TREATMENTS.
• 30% NH3OH:CH3OH = 1:1, room temperature, overnight
• I N N a O H , 75°C, 3 hours
• acetic anhydride-.glacial acetic acid=2:3, 150°C, 48 hours
• 1 N acetic acid, 100°C, 45'
• V. cholera neuraminidase, 0.1 U/ml, 37°C, overnight
• 2 N methanolic HC1, 75°C, 5 hours
* 0.5 N methanolic HC1,100°C, 2 hours
- 5 0 % HF, 48 hours, 0°C
- bacterial alkaline phosphatase, 0.04 U/ml, 37°C, overnight
> proteinase K, 1.6 m U / m l , 37°C, overnight •
• 0.5 M N a B H 4 in 3 M N a O H , room temperature, overnight
- 2 m M NaI0 4 in 7 0 % ethanol, room temperature, overnight
• 3 0 % H 2 O z in lOuM FeSCv room temperature, overnight
• 0.25 M nitrous acid in 0.1 M acetate buffer, p H 3.8, 8hrs,
room temperature

Table VII. IMF-1 (10-50 units) w a s treated as listed or m o c k treated by
leaving out the destructive agent as a control. Reactions were stopped by
separating IMF-1 from the destructive agent by evaporation or by resuspension
of IMF-1 into the butanol phase of a butanoLwater=l:l two phase system.
IMF-1 w a s then dissolved in PBS and tested against the mock-treated control
in the rosetting assay. In all cases, activity remained in both the treated and
control samples. In addition, phosphatidylcholine (5 ug) or G ^ (5 ug) or
some other lipid containing a susceptible linkage was cleaved or mock-treated
in parallel with IMF-1. Quantitative destruction of this control compound was
verified by thin layer chromatography.
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acidic
lipid
glycerol based
sphingosine based
isoprenoid
protein / peptide with fatty acid tail
prostaglandin or other fatty acid
ester - linked
long chain fatty acids
and / or
base phosphate group
essential to
IMF-1 activity

ganglioside

sensitive to base?
acetic anhydride 7

f N
sensitive to
asialylation ?
neuraminidase 7

f N
sphingosine
or glycerol
backbone

sensitive to
acid hydrolysis?
^

N

sensitive to
phosphatase 7
hydrofluoric acid 7

phosphate group
essential to
activity

^

N

sensitive to
proteinase K ?

protein + / •
fatty acid

f N
primary amine
essential to
activity

sensitive to
nitrous acid?

f N
* ruled out because IMF-1
does not absorb x > 2 1 4 n m
# w o u l d not partition to
aqueous phase in Folch cut

isoprenoid acid
acidic peptide + lipid tail'
prostaglandin * #
fatty acid #

Figure 18. Flow chart summary of chemical analysis of IMF-1. See text for
discussion.
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It m a y be useful to exploit the properties of IMF-1 outlined above to
devise more efficient purification protocols. For example, when IMF-1 is
extracted from a neutrophil homogenate treated with 0.16 N sulfuric acid, the

resulting chloroform/methanol extract of the cellular material is far less turbid.
This result suggests contaminating lipids in the IMF-1 extract may be removed
due to their susceptibility to acid or other treatments that do not affect IMF-1.
However, the IMF-1 produced by such a method would have to be compared
with IMF-1 prepared in the standard purification protocol to verify that acid
or other treatments did not change the nature of IMF-1 without destroying its
activity.
One chemical treatment that was found to destroy IMF-1 activity was
ozonolysis (table VIII). This treatment adds oxygen across carbon-carbon
double bonds and results in double bond cleavage, forming two aldehyde
molecules. Ozone is consumed as it reacts with targets, making ozone the
limiting factor in these reactions and for this reason destruction of IMF-1 could
be observed using C18-purified IMF-1 but not partially purified IMF-1. It is
unlikely that the treatments listed in table VII were ineffective due to the
presence of competing contaminants since, in the non-enzymatic reactions, a
large excess of the destructive reagents were added in each case. In all the
treatments listed, a parallel reaction was run in which a molecule containing
a susceptible structure was quantitatively destroyed, as monitored by TLC.
Due to the inability to detect IMF-1 by physical means, IMF-1 was followed
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OZONOLYSIS

DESTROYS

IMF-1 ACTIVITY

stimulus binding of EC3bi (Al)
resting PMN 139
PMA

1000

partially purified IMF-1, 58 U/ml 445
purified IMF-1, 58 U/ml 500
purified IMF-1, + O3,175 U/ml

95

Table VIE. IMF-1 (partially purified or purified by size exclusion
chromatography) in ethyl acetate w a s treated with 2 p p m 0 3 for 15' at 20°C
0 3 was generated by passing a stream of oxygen over an ultraviolet light
source. Samples were dried down, and residue dissolved in PBS. IMF-1
activity w a s assessed in the rosetting assay.
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by the loss of bioactivity after treatment, leaving open the possibility that IMF1 was cleaved but the bioactivity was unaffected.
IMF-1 has a molecular weight of approximately 340 daltons.
Size exclusion chromatography was used to determine the molecular
weight of IMF-1. A TSK G2000HXL size exclusion column with a separation
range of up to 2000 daltons was used. An isocratic run in tetrahydrofuran
separated molecular weight standards to yield a calibration curve shown in
figure 19 by the dark triangles. IMF-1, as measured by the rosette-inducing
activity in each fraction, ran at 6.4 and 9.4 ml (histogram). Peaks of IMF-1
activity do not correspond to peaks of absorbance at 254 nm, as expected from
the UV spectrum data. The 9.4 ml fraction corresponds to a molecular weight
of 340 daltons + 16. The 6.4 ml fraction is in the excluded volume of the
column, suggesting that the IMF-1 running there is in micelles, since it has a
molecular weight »2000. Rerun of the material eluting at the excluded
volume (figure 20) yielded the two molecular weight species of IMF-1 activity.
A rerun of the 340 MW fraction, after mixing with phosphatidylcholine (figure
21), also yielded the two forms of IMF-1. It appears that the two IMF-1

activities are in eqiiilibrium with each other because they can interconvert and
thus correspond to the same molecule running in either a monomeric (340) or
micellar (»2000) form. The possibility exists that the apparent IMF-1
molecular weight of 340 daltons is inaccurate due to interactions between IMF1 and the column sorbent or tetrahydrofuran. Fractionation of IMF-1 on a
distinct sizing column or on this column but using a different solvent might
60
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Figure 19. Size exclusion chromatography on IMF-1.
IMF-1 was separated on a T S K G 2 0 0 0 H X L size exclusion chromatography
column run in tetrahydrofuran. Elution volumes of polystyrene molecular
weight standards in the range of 1000 - 180 daltons are shown (triangles).
Linear regression yields a standard curve of y = -1.278x + 3.302 with r2=0.9884.
IMF-1 activity (histogram) of each fraction was determined by rosetting assay.
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Figure 20. Sixe exclusion chromatography on the excluded volume IMF-1
activity.
60 U of partially purified IMF-1 w a s run on a T S K G 2 0 0 0 H X L column
as described in figure 19. The fraction in the excluded volume of the column
containing IMF-1 activity w a s dried d o w n and resuspended into
tetrahydrofuran. Rechromatography yielded IMF-1 activity eluting at two
positions, as determined by rosetting assay on material in each fraction. This
experiment is representative of five repeats.
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Figure 21. Sixe exclusion chromatography on the 340 dalton IMF-1 activity.
330 U of partially purified IMF-1 w a s run on a T S K G 2 0 0 0 H X L column
as described in figure 19. The fraction eluting at a position corresponding to
a molecular weight of 340 daltons was dried d o w n and resuspended into
tetrahydrofuran containing 100 ug phosphatidylcholine (dilinoleoyl).
Rechromatography yielded IMF-1 activity eluting at two positions, as
determined by rosetting assay on material in each fraction. Absorbance of
eluting material was not recorded due to detector malfunction.
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help to rule this out.
IMF-1 is not equivalent to leukotriene B4 or lipoxin A4.
The apparent molecular weight of of IMF-1 of 340 daltons argues against
a ganglioside structure (MW>1000), as well as a glycerophosphatide

(MW>500), but it is suggestive of an eicosanoid. To rule out leukotriene B
(LTB4) and lipoxin A4 (LXA4), two candidate eicosanoids that function as
neutrophil agonists (table DC, and SD Wright, unpublished), IMF-1 was
runalongside 3H-LTB4 and LXA4 on a Waters uBondaPak C18 reverse phase
column (figures 14 and 15). The gradient was 1% per minute water to

acetonitrile run from 0-60% acetonitrile (see solid line on graph for gra

profile). These conditions were known from previous runs on this column t

elute IMF-1 at 45-50% acetonitrile. The LTB4 elution position was monitore
by cpm present in each fraction (dashed line), LXA4 was monitored by
absorbance at 254 nm (dotted line) and IMF-1 position was verified by

assaying fractions for activity in the rosetting assay (histogram corresp
attachment index). Neither eicosanoid coeluted with IMF-1. Moreover,
concentrations of LTB4 or LXA4 capable of activating CR3 gave large peaks
absorbance at 254 nm.
IMF-1 does not appear to be one of the known lipid products of PMN.
PMN are known to produce a number of lipids in response to cellular

activation including arachidonate metabolites and platelet activating fac
(PAF) (Henson et al.,1988). Table VI shows that IMF-1 is not identical to

since a PAF receptor antagonist has no effect on IMF-1-induced rosetting.
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Lipoxin A4 increases CR3 binding to C3bi-coated erythrocytes

stimulus

Al

PMN alone 56
lipoxin A4
50 ug/ml
5 ug/ml
500 ng /ml
50 ng/ml

313
288
109
48

Table IX. Various concentrations of lipoxin A 4 were applied to P M N for 15
minutes and binding to EC3bi was measured in the rosetting assay.
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A major class of bioactive lipids produced by P M N are derived from
arachidonic acid. Arachidonate is liberated from the 2 position of glycerol in
membrane phospholipids by the action of phospholipase A2 (Roberts et
al.,1977). It is then metabolized by cyclooxygenase to prostaglandins and by
lipoxygenases to leukotrienes, lipoxins and other hydroxylated eicosanoids.
PMN were incubated with inhibitors of 5-lipoxygenase (MK886 (Rouzer et
al.,1990) and L-651,392 (Guindon et al.,1987), kindly provided by Dr. S.
Longpre, Merck), cyclooxygenase (indomethacin), and phospholipases A2 and
C (bromophenacyl bromide) (Roberts et al.,1977) and in all cases, the inhibitor
alone or in combination with PMA or IMF-1 did not change the extent of CR3
binding to EC3bi over that seen in parallel wells which were not exposed to
the inhibitor (table X). These data suggest IMF-1 is not PAF or a leukotriene,
lipoxin, prostaglandin or other arachidonate metabolite. To verify that these
inhibitors did block release of arachidonate and subsequent metabolism, PMN
will be loaded with radioactive arachidonate and metabolites will be measured
in control and drug-treated cells. These experiments are ongoing.
Production of IMF-1 requires a mevalonate precursor.
To address the possibility that IMF-1 is an isoprenoid, an attempt was
made to block production of IMF-1 in response to agonists by blocking the rate
limiting enzyme in isoprenoid synthesis, HMGCoA reductase (figure 22). A
competitive inhibitor of the enzyme, lovastatin (40 ug/ml), was added to the
cells to block enzyme activity. Then, to deplete the cells of any IMF-1
precursors that had passed this early step in the synthesis pathway,
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INHIBITORS OF PRODUCTION OF ARACHIDONATE METABOLITES
DO NOT AFFECT CR3 ACTIVATION
inhibitor

attachment index

MK886, 50 n M
+ IMF-1

+ PMA
L651,392, 5 u M

+ IMF-1
+ PMA
none

+ IMF-1
+ PMA

indomethacin, 10uM

+ IMF-1
+ PMA
none

+ IMF-1
+ PMA

bromophenacylbromide, 3 u M

+ IMF-1
+ PMA
none

+ IMF-1
+ PMA

37
423
431
51
406
424
52
417
400

20
160
403
26
209
358

31
336
425
23
340
471

Table X. P M N were treated with indomethacin (1000, M K 8 8 6 (500, L651,392
(500 or bromphenacylbromide (700 in the rosetting assay, in the presence or
absence of IMF-1 (42 U/ml) or P M A (30 ng/ml). EC3bi were allowed to
adhere to cells for the last 15 minutes of incubation. These experiments are
representative of at least two repeats.
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Acetyl CoA + Acetoacelyl CoA

•> Isopentenyl Adenine
(tRNA)
Dolichol
>Haem A
> Ubiquinone
> Farnesylated Proteins
(Ras, lamin B, others)
•> Steroid Hormones
> Vitamin D
> Bile Acids
> Lipoproteins

Plasma LDL

Figure 22. The mevalonate pathway in animal cells, (from Goldstein and
Brown, 1990)
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C5a (10*8M) w a s added. C5a transiently activates cells without leaving them
refractory to subsequent stimulation by PMA (Lo et al.,1989). Lovastatintreated cells, briefly pulsed with C5a, were then activated with PMA to see if
PMA could cause production of IMF-1 despite the block in isoprenoid
production. PMA could not increase rosetting in the lovastatin-blocked cells,
but could when the block was overcome by adding mevalonate, the product
of HMGCoA reductase, to the media (table XI). This experiment supports
thepossibility that IMF-1 is a downstream product of the mevalonate synthesis
pathway or that the generation of IMF-1 requires a mevalonate metabolite.
In order to differentiate between these two possibilities, PMN were
labeled with [3H]-mevalonate and then extracted for IMF-1. It is known from
metabolic labeling with 2-[14C]-acetate or [14C]-mevalonate that PMN can
synthesize squalene but not sterols (Fogelman et al.,1977). Cells were
incubated with [3H]-mevalonate for 2 hours in the presence of lovastatin, to
ensure uptake of exogenous mevalonate. Early in the incubation, IMF-1
precursor was cleared by adding C5a. For the final 15' of incubation, cells
were activated with TNF, in order to stimulate IMF-1 production, before being
extracted with organic solvents. 12% of the counts added to the cells were
found in the lipid extract derived from the cell pellet. Only background levels
of counts coeluted with the IMF-1 in the pellet extract on C18 reverse phase
chromatography (figure 23). The presence of several peaks of radioactivity in
the chromatogram suggest that label was incorporated into mevalonate
metabolites. This experiment suggests that IMF-1 itself is not a product of the
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GENERATION OF IMF-1 REQUIRES A PRODUCT OF THE MEVALONATE PATHWAY
stimulus binding of EC3bi (Al)
experiment 1

experiment 2

resting P M N
lovastatin
lovastatin + C5a
C5a + P M A

32
48
86
ND

19
ND
37
309

lovastatin + C5a + P M A
lovastatin, mevalonate, C5a +PMA

74
465

50
281

IMF-1
lovastatin, C5a +IMF-1

511
302

277
279

Table XI. Adherent P M N were incubated in lovastatin (40 ug/ml) for 90
minutes at 37°C in the presence or absence of mevalonate (50 ug/ml). Cells
were transiently activated with C5a (10"8M) during the incubation and were
treated with P M A (30 ng/ml) or IMF-1 (42 U/ml) for the last 20 minutes of the
incubation. These two experiments are representative of four
repeats.
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Figure 23. IMF-1 from [3H]-mevalonate labelled PMN is not radioactive.
P M N (2 x IO8) were incubated with 500 uCi of [3Hl-mevalonate in the presence
of lovastatin (40 ug/ml) for 2 hours at 37°C. Cells were transiently activated
with C5a during the incubation and were treated with T N F (5 x 10^ U/ml) for
the last 15 minutes of the incubation. Cells were pelleted and extracted with
chlorofonrumethanol:water=10:10:l. About 1 2 % of the counts added were
present in this extract. Half of the extract was dried d o w n under N 2 ,
resuspended into 2 0 % C H 3 C N (aq), and separated by C 1 8 reverse phase
chromatography. IMF-1 activity eluted at the position indicated by the arrow.
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mevalonate pathway, although it is possible that insufficient label was
incorporated into the IMF-1 pathway to allow detection.
GC-MS analysis reveals a candidate peak of 315 daltons
70,000 units of IMF-1 were purified by C18 reverse phase
chromatography, derivatized with trimethylsilane (TMS) and loaded onto a
capillary gas chromatography column attached to an electron ionization mass
spectrometer. Fractions from the reverse phase column containing the IMF-1
activity peak were compared to fractions eluting on either side of the activity
peak to rule out common contaminants. Figure 24 shows the IMF-1 GC profile

(top) compared to the trailing edge fractions containing slight levels of activi
(middle) and leading edge fractions, lacking IMF-1 activity (bottom). A peak
(arrowhead) appearing in the sample from fractions with high IMF-1 activity
was absent in the sample from fractions with no IMF-1 activity (bottom) and
was very small in sample from fractions with trace amounts of IMF-1 activity
(middle). A mass spectrum of this peak is shown in figure 25. The top panel
shows the TMS derivative while the bottom panel shows the deuterated-TMS
derivative. Differences in peak mass between the two spectra show the
molecule has two derivatizable groups, which could include hydroxyl,
carbonyl or carboxyl oxygens. TMS derivatives give much stronger signals for
the mass ion minus a methyl group than they do for the mass ion itself.
Given that fact, the molecule has a molecular weight of 315 daltons
(444(M+TMS2-CH3) - 144(2 x TMS) + 15(CH3)). The peaks with the highest
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Capillary GC retention

time

•

Figure 24. G a s chromatography of purified IMF-1.
70,000 units of partially purified IMF-1 was purified on a C 1 8 Waters
uBondapak reverse phase column (lOum particle size, 3.9mm x 150 m m ) in a
1 % per minute gradient of 20 - 6 0 % acetonitrile (aq). Elution of IMF-1 at 4 7 %
C H 3 C N w a s verified by testing column fractions by rosetting assay. Purified
IMF-1 (top tracing), as well as material from fractions eluting just before
(bottom tracing) and after (middle tracing) those containing IMF-1 activity,
was derivatized with trimethylsilane (or deuterated T M S ) using 1:1=BSTFA
(Sigma):pyridine, 50°C, 30* and loaded onto a capillary gas chromatography
column in series with an electron ionization mass spectrometer.
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Figure 25. M a s s spectrum of purified IMF-1.
Spectrum of peak indicated by arrowhead on figure 24. Peak was chosen
because it was present in IMF-1-containing fractions but absent in those
eluting just before IMF-1 activity, and slight in the fractions following, which
contained a low level of IMF-1 activity. The array of fragments shown suggest
the peak represents a molecule of underivatized M,. of 315 daltons. See text for
discussion.
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signals represent two fragments of molecular weights 143 and 172 (317 -144(2
x TMS) = 173; 244 - 72(1 x TMS) = 172; 215 - 72(1 x TMS) - 142). The 172/173
fragment probably has a carboxyl group, explaining the fact that the fragment
can be singly or doubly silylated, and why the molecular weight varies by one,
representing the hydroxyl hydrogen. The two predominant fragments of 143
and 172 daltons suggest the presence of a labile bond at roughly the center of
the molecule that is directing preferential cleavage at that site. The presence
of two predominant fragments also suggests the molecule is not a simple
hydrocarbon. The odd molecular weight suggests the presence of a molecule
with an odd valency, most likely nitrogen. The absence of a characteristic
isoprene fragment of 69 daltons means either the molecule is not an isoprenoid
or that the ultimate isoprene repeat(s) on the molecule are saturated, with a
molecular weight of 71 daltons, and lack the double bond that directs cleavage
of that fragment. The GC-MS analysis will have to be performed on another
preparation of IMF-1, preferably containing more material, in order to verify
that appearance of this 315 dalton peak correlates with the presence of IMF-1
activity.
In summary, its physical properties suggest IMF-1 is an acidic,
amphiphilic lipid. IMF-1 appears to be distinct from the known lipid products
of PMN. It has an absorbance maximum at 196 nm and a molecular weight
of 340 daltons by size exclusion chromatography. IMF-1 or a molecule
involved in its synthesis may be a product of the mevalonate pathway. More
studies are required to determine the chemical nature of the molecule.
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Chapter 5 - further studies on the biology of IMF-1
IMF-1 does not behave like known agonists of PMN
IMF-1 is a molecule that can be extracted from PMN treated with
agonist and that can enhance the binding of CR3 to its ligand, C3bi. IMF-1

appears to regulate CR3 function by acting directly on the receptor (figure 10).
However, like an agonist, IMF-1 could cause intracellular responses in addition

to its effect on CR3. To rule this out IMF-1 was tested for typical agonist-like
properties.
Agonist-treated PMN become refractory to restimulation with the same
agonist. This property of homologous desensitization is illustrated for PMA
in figure 26a, and has also been observed for other agonists such as NAP-l/IL8 (PA Detmers, unpublished) and C5a (Webster et al.,1980). After treating
PMN for 60 minutes with PMA, CR3 activity declined and did not increase
upon readdition of PMA (open square, figure 26a). Cells treated for 60
minutes in PMA remained viable and addition of IMF-1 caused increased
binding to EC3bi (open triangle, figure 26a). In contrast, cells treated for 60
minutes with IMF-1 exhibited enhanced binding of EC3bi in response to either
IMF-1 or PMA (figure 26b), indicating the absence of homologous
desensitization to IMF-1.
Agonists of PMN trigger fusion of specific granules (also known as
secondary granules) with the plasma membrane. No degranulation occurred
in response to doses of IMF-1 as high as 42 U/ml (figure 27). These data
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Figure 26.
IMF-1 does not cause homologous or heterologous
desensitization.
P M N were treated for up to 1 hour with P M A (panel A, 30 ng/ml, closed
squares, solid lines) or IMF-1 (panel B, 42 U / m l , partially purified from fNLLP
treated cells, closed triangles, dashed lines). Binding of EC3bi was measured
in the rosetting assay. At 60 minutes, replicate cultures were washed and then
treated with either IMF-1 (panels A and B, open triangles, dashed line) or
P M A (panels A and B, open squares, solid line) as indicated before attachment
index for EC3bi was measured. This data is the average of two experiments,
performed in triplicate, bars show the S E M .
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Figure 27. . IMF-1 does not cause degranulation of P M N .
P M N were incubated with lipid extracts or with P M A (30 ng/ml) for varying
times, washed and stained with monoclonal A b O K M 1 0 (5 ug/ml, 0°C, 200 to
ascertain levels of C R 3 expression. Huorescein-conjugated secondary antibody
was then added (10 ug/ml, 0°C, 200 and cells were analyzed by flow
cytometry. IMF-1 derived from cells treated with P M A or T N F (containing 17
U / m l and 42 U / m l IMF-1, respectively) had no effect on CDllb expression.
Lipid extracts from cells that lack IMF-1 (lipids from untreated P M N or from
P M N treated with P M A 600 also had no effect on C R 3 expression. Identical
results were obtained in three separate experiments.
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suggest that IMF-1 does not initiate signal transduction as do classical agonists
and thus appears to act simply as an allosteric activator of CR3. The
more pronounced increase in EC3bi binding (figure 26) triggered by PMA or
by IMF-1 after PMA treatment, compared to IMF-1 alone, could be explained
by the fact that PMA causes degranulation of PMN, leading to increased cell
surface CR3. Since IMF-1 does not cause degranulation it only affects the CR3

already at the surface. Thus IMF-1 has a greater effect on cells already treated
with PMA than it does on naive or IMF-1-treated cells.
IMF-1 affects the ability of CR3 to bind several ligands.
CR3 binds several ligands in addition to C3bi. PMN bind fibrinogencoated surfaces via CR3, and this binding can be enhanced by treating PMN
with PMA (figure 28) (Wright et al.,1989). Treatment of resting PMN with
IMF-1 also enhanced adhesion of PMN to fibrinogen-coated culture surfaces
in a transient fashion (figure 28), and this binding was inhibitable with mAbs
against CR3 (table XII), suggesting that IMF-1 regulates the ability of CR3 to
bind fibrinogen. The experimental design does not rule out the possibility that
IMF-1 interacts with fibrinogen rather than CR3 on the PMN. CR3 on PMN
also binds lipid IVa, a biosynthetic precursor of lipopolysaccharide (Wright et
al.,1988), and this binding can be enhanced by treating PMN with agonists
such as NAP1/IL8 (Detmers et al.,1990). Treatment of resting PMN with IMF1 enhanced binding of erythrocytes which have lipid IVa incorporated into the
surface leaflet of the plasma membrane (AI=13 without vs. AI=117 with IMF1; n=3), suggesting that the ability of CR3 to bind lipid IVa is also regulated
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Figure 28. IMF-1 causes increased binding of C R 3 to fibrinogen.
P M N were allowed to adhere to fibrinogen-coated surfaces at 37°C for varying
times in the presence (squares) or absence (triangles) of P M A (30 ng/ml, open
squares) or IMF-1 (42 U/ml, partially purified from fNLLP treated cells, solid
squares). Data points are the average of two experiments, two wells each.
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IMF-l-INDUCED BINDIN&OF PMN TO FIBRINOGEN IS CD18-DEPENDENT

stimulus

antibody

antigen

200+120

none
IMF-1
IMF-1
IMF-1

cells bound per m m

IB4
W6/32

CD18
MHCclI

680+170
220+140
560+220

Table XII. P M N were incubated in fibrinogen-coated culture wells for 30
minutes at 0°C in the presence of m A b s (10 ng/ml) and then IMF-1 (42 U/ml,
isolated from cells treated with fNLLP) was added for 30 minutes at 37°C.
Wells were washed with PBS and bound cells were scored by phase contrast
microscopy. These data are the average of two experiments, performed in
duplicate.
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by IMF-1.

CR3, as well as its close homologue, LFA-1, are necessary for the process
of diapedesis (Harlan et al.,1985; Anderson and Springer, 1987; Todd and

Freyer, 1988; Lo et al.,1989). Treatment of resting PMN with IMF-1 increas

their ability to adhere to unstimulated EC (figure 29). IMF-1-induced bin

of PMN to EC was dependent on IMF-1 concentration and exhibited transient

kinetics (figures 30 and 31). Binding was blocked nearly completely by an
antibody against the p chain common to CR3 and LFA-1 (figure 29, IB4) or
a combination of antibodies against the a chains of these two receptors
(TS1/22 against LFA-1 a chain, OKM10 against CR3 a chain). Antibodies
against either the LFA-1 or CR3 a chain alone blocked only about half of

binding of PMN to EC, as did an antibody against the LFA-1 counter-recept
ICAM-1. Thus, IMF-1 appears to regulate the ability of both LFA-1 and CR3
to bind structures on the surface of EC.
IMF-1 modulates the binding activity of LFA-1.
LFA-1 on lymphocytes also exhibits a regulated binding activity:
stimulation with PMA enables LFA-1 on lymphocytes to bind ICAM-1 on
adjacent lymphocytes and cause homotypic aggregation (Patarroyo and
Makgoba, 1989). Addition of IMF-1 to lymphocytes also caused aggregation
of the cells that could be blocked by addition of a mAb directed against
a chain of LFA-1. MAb to CR3 a chain had no effect on the aggregation

response (figure 32). Lipids extracted from cells that were not stimulate
agonist and therefore lacked IMF-1 (control lipids, figure 32) could not
82

600 i

CM

E
6

*2 0

400-

1!

CL

c
O
-Q

200-

fa fa

I
I,

3
2
2
2
%
3
2
2
4* V,
%
2
2 2 2
—

against:
stimulus:

Q

O

<o

•»-

>- 1

-Q

-Q

»-

+

IMF-1

none

P?

I

CC
CD11

QO

mAb

ICAI

CH

= —
cc o
HJ
o O
u.
1

Figure 29. IMF-1 causes increased binding of P M N to unstimulated
endothelium.
P M N were treated with IMF-1 (42 U/ml, isolated from cells treated with
fNLLP), washed, and allowed to bind to unstimulated human umbilical vein
endothelial monolayers in the presence or absence of mAbs (10 ug/ml). The
m A b s used were O K M 1 0 against CDllb, TS1/22 against CDlla, LB2 against
ICAM-1, IB4 against CD18, W 6 / 3 2 against M H C class I and 3G8 against
FcRIII. Nonadherent cells were then washed away and bound cells were
quantitated using phase contrast microscopy. Values are the average of
duplicate wells, bars show the SEM. This experiment is representative of three
separate experiments.
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Figure 30. IMF-1-induced binding of P M N to endothelium is transient
P M N were treated with IMF-1 (42 U/ml, isolated from cells treated with
fNLLP) for varying times, washed and allowed to bind to unstimulated
endothelial monolayers. Values are the average of two experiments, duplicate
wells. Bars show the SEM.
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Figure 31. IMF-1 induces binding of P M N to endothelium in a dosedependent manner.
P M N were treated with IMF-1 (isolated from cells treated with fNLLP),
washed and allowed to bind to unstimulated endothelial monolayers. Values
are the average of two experiments, duplicate wells. Bars show the SEM.
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Figure 32. IMF-1 causes lymphocyte aggregation mediated b y LFA-1.
Lymphocytes were purified on Percoll gradients and contaminating monocytes
were removed by plastic adherence. Cells were then added to Terasaki plate
wells and P M A (100 ng/ml), IMF-1 (42 U / m l ) or lipids extracted from resting
P M N ("control lipids", extracted from 3 times as m a n y cells as the IMF-1) were
added in the presence or absence of antibodies (10 ug/ml). TS1/22 and
O K M 1 0 are against C D l l a and CDllb, respectively. IB4 is against C D 1 8 .
W 6 / 3 2 recognizes M H C class I. Aggregation w a s determined by phasecontrast microscopy. Similar results were obtained in three separate
experiments.
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LFA-1-dependent aggregation. Thus, IMF-1 appears to affect the function of
both CR3 and LFA-1.
IMF-1 can be extracted from other leukocytes.
Lipid extracts derived from monocytes, macrophages and a monocytoid
cell line (THP-1) were all found to have IMF-1 activity in the rosetting assay
(table XQI). These results suggest that cells of the monocyte lineage, in
addition to granulocytes, make IMF-1. It is interesting to note that resting
macrophages contain IMF-1 and that these cells also bind EC3bi molecules.
Since lymphocytes are able to respond to the IMF-1 extracted from PMN
in a manner similar to their response to PMA, lymphocytes were extracted for
lipids to see whether they contain IMF-1, especially after stimulation with
PMA. IMF-1 was only recovered in very small quantities from lymphocytes
and from an EBV-transformed B cell line (SCHU), and amounts extracted were
similar before and after treatment with PMA (table XIII). The lymphocyte
lipid extracts were inactive in the lymphocyte aggregation assay and only
active at very slight dilution in the rosetting assay for binding to EC3bi,
suggesting quantities of IMF-1 present were at or below the threshold of
sensitivity for these assays. These results leave open the possibility that
although lymphocytes respond to neutrophil-derived IMF-1, they may use a

different, IMF-1-like, molecule for regulation of LFA-1, which is not extractable
by the IMF-1 purification method. The neutrophil-derived IMF has been
designated IMF-1 to leave open the possibility that other IMFs will be found.
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EXTRACTION OF IMF-1 FROM VARIOUS CELL TYPES
U/107 cells
THP-1, differentiated
THP-1, differentiated, +PMA
THP-1
THP-1, membrane fragments
and organelles
THP-1, microsomes

3
1

macrophages
monocytes

>1
5

lymphocytes

<05

S C H U (B cell line)

<025
<0J25

SCHU + PMA

16-25
5-16

10

Table XHI.
Lipids were extracted from at least IO8 cells as described in chapter 2.
The number of units of IMF-1 in a partially purified lipid extract w a s
determined by rosetting assay.
P M A (30 ng/ml) was added to differentiated THP-1 cells (5 x lOVml)
or S C H U cells (2 x lOVml) for 30 minutes at 37°C before harvesting. THP-1
cells (5 x lOVml) were treated with recombinant granulocyte monocyte colony
stimulating factor (80 p M ) and vitamin D 3 (10"* M ) for 72 hours at 37°C to
induce differentiation. Subcellular fractions of THP-1 cells were kindly
provided by Dr. D . Miller (Merck Sharp and D o h m e Research Laboratories,
N.J.). Subfractionation of homogenized THP-1 cells w a s performed by spinning
cells at 10,000 x g for 10 minutes to remove nuclei and unbroken cells, then
spinning at 23,600 x g for 20 minutes to remove organelles and large
membrane fragments and 240,000 x g for 60 minutes to remove microsomes.
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Representative pi and p3 integrins do not respond to IMF-1
Experiments were performed to test the ability of IMF-1 to affect
integrins other than LFA-1 and CR3. Stimulation of platelets with agonists
such as thrombin leads to aggregation, due to activation of the ability of the
integrin gpIIb/HIa (ocIIbp3) to bind soluble fibrinogen. IMF-1 was added to
unstimulated platelets to test whether IMF-1 is involved in regulation of
Ilb/nia binding. The cells exhibited no change in aggregation state in
response to doses of IMF-1 as high as 100 U/ml (figure 33), although they
readily aggregated in response to thrombin. IMF-1 also was unable to convert
gpnb/IIIa to an activated configuration, as detennined by an inability of IMF1-treated platelets to bind PAC1, a mAb that only recognizes activated receptor
(table XTV). These data suggest IMF-1 is not responsible for regulation of this
p3 integrin.
VLAs -4 and -5 on T cells bind more avidly to fibronectin-coated
surfaces upon stimulation of the cells with PMA (Shimizu et al.,1990).
Exogenous IMF-1 was unable to increase VLA binding to Fn (table XV)
suggesting increased binding in response to PMA is not due to IMF-1
production. These results show that IMF-1 itself is not responsible for the
regulated binding activity of these representative Pj and p3 integrins.
However, the data do not rule out the existence of other related molecules that
could regulate these integrins.
To summarize the biological properties of IMF-1, it is produced
monocytes and macrophages as well as by PMN. It increases the binding
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Figure 33. IMF-1 is not involved in platelet aggregation.
Aggregation of platelets (2 x lOVml), as measured by an increase of light
transmittance, was monitored in response to 100 U / m l of IMF-1 and 3 U / m l
of thrombin.
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IMF-1 does not convert gpDb/nia to an active configuration

mAb

stimulus

MFC

none

none

13.85

FITC-PACl

none

14.05

FITC-PACl

IMF-1

14.89

FITC-PACl

ctrl lipids

17.16

FITC-PACl

thrombin

63.70

Table XIV. Platelets (IO6) were incubated for 15', 20°C with IMF-1 (50 U/ml),
lipids from unstimulated P M N ("ctrl lipids") or thrombin (0.2 U/ml) and
stained with uuorescein-conjugated P A C 1 m A b , which only recognizes the |33
integrin gpHb/HIa in its active form. Platelets were analyzed by flow
cytometry. M F C = m e a n fluorescent channeL
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IMF-1 DOES NOT INCREASE BINDING OF VLA-4 AND VLA-5 TO FWRONECTIN

cells bound per m m

587 + 46

lymphocytes alone

2,667 + 606
560 + 80
2,667 + 378

+10 ng/ml PMA
+PMA + anti-pl m A b
+PMA + anti-p2 m A b

667 + 122

+42 U/ml IMF-1

Table XV. Lymphocytes were allowed to bind to fibronectin-coated surfaces
in the presence or absence of P M A or IMF-1 (partially purified from fNLLPtreated P M N ) . Specificity of binding w a s verified with m A b A H B 2 against pj
and IB4 against ^. Adherent lymphocytes were quantified by phase contrast
microscopy. These data are the average of three repeats; error is the S E M .
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activity of both purified and native C R 3 for a variety of ligands, as well as
increasing the binding activity of LFA-1. IMF-1 is not secreted by activated
PMN, but rather remains cell-associated. IMF-1 appears to have a mode of
action distinct from that of neutrophil agonists, and its effect is specific for
integrins on PMN, since FcR activity remains unaffected by IMF-1 treatment.
While IMF-1 affects leukocyte integrins, it appears to be unable to change the
binding activity of fa and p3 integrins.
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Chapter 6 - Discussion
Adhesion events are often regulated
Many adhesion interactions occur only at precise times and locations.
Cells must find their place in the developing embryo, mitotic cells must detach
from the extracellular matrix during cell division, platelets must aggregate
during coagulation and immune cells must extravasate to sites of inflammation
or find their infected target and kill it.
Many of the adhesion molecules involved in these interactions have
regulated activities. In the course of development, the immunoglobulin
superfamily member NCAM is converted from an embryonic form with high
sialic acid content, to an adult form with lesser amounts of this sugar, and
exhibits a corresponding increase in binding activity (Hoffman and Edelman,
1983). N-Cadherin-mediated adhesion is modulated in chick retinal neurons
by an associated N-acetylgalactosaminylphosphotransferase (Balsamo et
al.,1991). The LECCAM family member leukocyte adhesion molecule-1 (LAM1), involved in leukocyte migration, exhibits increased binding activity on
lymphocytes and PMN activated with lineage-specific stimuli (Spertini et
al.,1991).
Many of the members of the integrin superfamily of adhesion molecules

can regulate their ability to bind ligand. Gp Ilb/IIIa (otvP3), found on platelets,
binds poorly to its substrates until the platelet is activated by a variety of
prothrombotic stimuli, such as ADP or thrombin (Plow and Ginsberg, 1989).
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V L A antigens (a4pa and a5fa integrins) on T cells can bind to extracellular
matrix components more efficiently after the lymphocytes are activated
(Shimizu et al.,1990). a6fa on macrophages adheres to laminin after cells are
activated with PMA (Shaw et al.,1990). a6fa in developing retinal neurons can
lose its ability to bind laminin during the course of maturation of the chick
embryo, although levels of mRNA and protein remain unchanged (de Curtis
et al.,1991). Phorbol esters can increase or decrease the binding of a5p1 to
fibronectin in CHO or K562 cells, respectively (Danilov and Juliano, 1989;
Symington et al.,1989). LFA-1 (aLp2, CD1WCD18) adhesiveness on T cells is
enhanced after TcR crosslinking, treatment with PMA, incubation with mAbs
to CD44 or LFA-1 itself, or upon binding of ligand to MHC class II (Dustin
and Springer, 1989; Patarroyo and Makgoba, 1989; Koopman et al.,1990; Keizer
et al.,1988; Mourad et al.,1990). LFA-1 adhesivity on monocytes is enhanced
in response to ligand binding to CD14 (Lauener et al.,1990). The molecular
basis of regulated adhesion in integrins has been studied by several
laboratories but remains to be elucidated.
A model for the regulation of integrin function
Integrins exhibit striking changes in their ability to promote adhesion
without corresponding changes in the number of receptors at the cell surface,
suggesting that changes in the nature of the existing receptors are responsible
for the alterations in adhesivity. Various mechanisms for regulation of
receptor function have been postulated. These include aggregation of receptors
in the plane of the membrane, phosphorylation or some other covalent
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modification of the receptor, changes in the microenvironment of the receptor,
or conformational change. Several results suggest that conformational changes
underlie the alterations in avidity of integrin receptors. Stimulation of
platelets causes a coordinate increase in the avidity of integrin gpIIb/IIIa
(0:^-3), and the induction of a neoepitope on the gpIIb/IIIa molecule,
suggesting that a conformational change accompanies activation (Coller, 1985;
Shattil et al.,1985). The avidity of pi (Neugebauer and Reichardt, 1991), p2
(Keizer et al.,1988; van Kooyk et al.,1991), and p3 (Kouns et al.,1990; OToole
et al.,1990) integrins can be strongly enhanced by incubation of cells with
certain monoclonal antibodies against the corresponding integrins, suggesting
that binding of these monoclonals can induce conformational changes
associated with activation. Platelet activation has been shown to lead to a
change in the spatial separation or orientation of exoplasmic domains within
gpIIb/IIIa, and this change in the receptor may serve to convert this integrin
into a functional adhesion receptor (Sims et al., 1991). Epitopes on each of the
two chains of gp lib/Hla on platelets were labelled with a mAb conjugated to
a donor fluorescein or an acceptor tetramethylrhodamine chromophore, and
fluorescence resonance energy transfer was measured by flow cytometry. In
response to activation, platelets exhibited a 2-fold increase in resonance energy
transfer. This increase occured independently of receptor occupancy and was
identical regardless of which Ab carried the donor chromophore. Moreover,
no energy transfer occured before or after platelet activation when lib/Ilia was
labelled with chromophore-conjugated mAb that recognizes the entire receptor
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complex. These data suggest receptors are not clustered: they are not in close
enough proximity to transfer energy between subunits on different receptors.
Most importantly, the avidity of purified gpEb/IIIa can be enhanced by pretreating the purified receptor with peptide ligands (Du et al.,1991), the avidity
of purified ocvp3 can be altered by reconstituting the purified receptor in
liposomes of different lipid compositions (Conforti et al.,1990), and the avidity
of purified CR3 can be altered by the addition of the lipid IMF-1. Purified
gpEb/IIIa has been shown to become sensitive to thrombin hydrolysis, and
exhibit changes in its intrinsic protein fluorescence, sedimentation coefficient
and Stokes radius when treated with synthetic peptides (Parise et al., 1987)
that are known to also increase the avidity of the receptor (Du et al., 1991).
In these studies, changes in avidity or physical properties are observed with
purified receptor, thus making it unlikely that other cellular proteins,
phosphorylation events or changes in the receptor microenvironment are
necessary for avidity changes and strengthening the notion that changes in
receptor conformation are sufficient to alter avidity.
This thesis addresses the mechanism by which the avidity of CR3 is
regulated and suggests the following model. In resting cells, CR3 exists in a
low avidity state. Upon stimulation with agonists such as PMA, PAF, fNLLP
and TNF, PMN synthesize or unmask the lipid IMF-1, which binds to CR3 and
effects a conformational change to a high avidity state. Degradation or
sequestration of IMF-1 then enables CR3 to relax to a low avidity state. In
support of this model, the data demonstrate that the level of IMF-1 present in
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cells corresponds to the avidity of their C R 3 and that addition of IMF-1 is
sufficient to increase avidity of CR3 on the cell surface or in purified form.
The data do not rule out the possibility that IMF-1 enhances ligand binding by
forming part of the binding site. However, the precedent set by work on other
integrins, showing conformational changes upon activation favors the
hypothesis that IMF-1 works as an allosteric activator of CR3 and LFA-1. It

is likely that the site on the receptor that interacts with IMF-1 is located in t
transmembrane domain, due to the hydrophobic nature of IMF-1. Mutational
analysis of LFA-1 (Hibbs et al.,1991) has shown that truncation of the p chain
cytoplasmic domain results in loss of sensitivity to phorbol esters. The data
presented here do not indicate whether association with IMF-1 is the only
means by which the conformation of CR3 can be altered or whether
conformational changes are the only means by which the avidity of CR3 may
be altered. It is possible that other, non-lipid molecules may also cause a
conformational change in CR3 to a high avidity state. Moreover, mechanisms
other than conformational change could participate in regulation of adhesion.
For example, activation of CR3 is tightly associated with clustering of CR3 in
the plane of the membrane (Detmers et al.,1987), and clustering of the ligand
C3bi on the surface of an erythrocyte is necessary for efficient recognition by
CR3 on PMN (Hermanowski-Vosatka et al.,1988). Clustering of receptors may
thus function either along with or in lieu of the conformational changes
addressed here to affect alterations of adhesivity.
Several workers have observed phosphorylation of CD18, and have
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suggested that this phosphorylation event m a y regulate receptor function
(Hara and Fu, 1986; Chatila et al.,1989; Merrill et al.,1990). IMF-1 can increase
the avidity of CR3 in the absence of cellular factors, suggesting that direct
phosphorylation is not required to change the avidity state of the receptor. In
addition, the time course of phosphorylation correlates poorly with that of
receptor activity, and only substoichiometric levels of phosphorylation of CR3
(less than 1% of total receptors) can be observed (CB Epstein and SD Wright,
unpublished). While these data suggest that phosphorylation does not control
ligand binding to receptor, it is possible that phosphorylation of CR3 plays a
role in signal transduction by the receptor, or that phosphorylation of a
molecule other than CR3 might be involved in triggering the production of
IMF-1 or regulating the rate of degradation of IMF-1 in stimulated PMN. In
keeping with the possibility that IMF-1 production is enhanced by a
phosphorylation event, thio-phosphate loading of PMN, which makes
phosphorylation events irreversible, has been shown to cause sustained
activation of CR3 (Wright and Meyer, 1986).
Much attention has been focused on the intracellular signals generated
by binding of hormones and other molecules to cell surface receptors. IMF-1
may provide an example of a less well studied phenomenon: inside-out
signalling. IMF-1 is a molecule which allows the cell to signal to its
extracellular milieu in response to intracellular perturbations. Studies of IMF-1
may lend insight into other cellular behaviors of this sort.
IMF-1 is not unique in providing an example of a lipid associating with
99

and modifying a receptor or channel. Fatty acids have been s h o w n to directly
affect the conductance of ion channels in the absence of soluble factors such
as nucleotides and calcium (Ordway et al.,1991). The ganglioside GM3 can
inhibit the EGF-stimulated autophosphorylation of isolated EGF receptor, and
phosphatidylethanolarnine can enhance this phosphorylation (Bremer et
al.,1986). Polysialogangliosides such as GTlb can increase autophosphorylation
of purified guinea pig muscle phosphorylase b kinase by 4-10 fold (Chan,
1989). Human and porcine thyrotropin receptors coisolate with a ganglioside
similar to GM1 (Kielczynski et al.,1991) and the integrins ccvp3 and a5p1
coisolate with gangliosides GD2 and O-acetylated GD3, respectively (Cheresh

et al.,1987; Stallcup et al.,1989). However, little evidence exists for cellular the
levels of production of these associated lipids.
By regulating the avidity of the leukocyte integrins, IMF-1 can in turn
be implicated in the regulation of diapedesis and the evolution of the
inflammatory response. Synthesis and degradation pathways for IMF-1 are
thus of great interest, and may prove clinically relevant targets for
pharmacologic intervention in the control of inflammation.
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